0000711404-22-000053 | 10-K | XBRL Viewer

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Income Statement [Abstract]
Net sales	$ 3,308.4	$ 2,922.5	$ 2,430.9
Cost of sales	1,168.8	966.7	896.1
Gross profit	2,139.6	1,955.8	1,534.8
Selling, general and administrative expense	1,342.2	1,211.2	992.5
Research and development expense	110.3	92.7	93.3
Amortization of intangibles	179.5	146.1	137.2
Operating income	507.6	505.8	311.8
Interest expense	57.3	23.1	36.8
Other (income) expense, net	(25.0)	(8.8)	8.5
Income before income taxes	475.3	491.5	266.5
Provision for income taxes (Note 6)	89.5	(2,453.2)	28.1
Net income	$ 385.8	$ 2,944.7	$ 238.4
Earnings per share (Note 7)
Basic (in dollars per share)	$ 7.83	$ 59.80	$ 4.85
Diluted (in dollars per share)	$ 7.76	$ 59.16	$ 4.81
Number of shares used to compute earnings per share:
Basic (in shares)	49.3	49.2	49.1
Diluted (in shares)	49.7	49.8	49.6

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 385.8	$ 2,944.7	$ 238.4
Other comprehensive (loss) income:
Cash flow hedges, net of tax of $26.1, $8.2 and $(4.1), respectively	81.3	26.1	(13.0)
Change in minimum pension liability, net of tax of $8.7, $7.2 and $(4.0), respectively	27.9	22.6	(12.8)
Foreign currency translation adjustment	(234.7)	82.0	0.9
Other comprehensive (loss) income	(125.5)	130.7	(24.9)
Comprehensive income	$ 260.3	$ 3,075.4	$ 213.5

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Statement of Comprehensive Income [Abstract]
Cash flow hedges, tax provision (benefit)	$ 26.1	$ 8.2	$ (4.1)
Change in minimum pension liability, tax provision (benefit)	$ 8.7	$ 7.2	$ (4.0)

Consolidated Balance Sheets - USD ($) $ in Thousands	Oct. 31, 2022	Oct. 31, 2021
Current assets:
Cash and cash equivalents	$ 138,200	$ 95,900
Trade accounts receivable, net of allowance for credit losses of $20.7 at October 31, 2022 and $9.2 at October 31, 2021	557,800	515,300
Inventories (Note 1)	628,700	585,600
Prepaid expense and other current assets	208,900	179,300
Assets held-for-sale	0	89,200
Total current assets	1,533,600	1,465,300
Property, plant and equipment, net	1,432,900	1,347,600
Goodwill (Note 4)	3,609,700	2,574,000
Other intangibles, net (Note 4)	1,885,100	1,271,500
Deferred tax assets	2,443,100	2,546,600
Other assets	587,900	401,200
Total assets	11,492,300	9,606,200
Current liabilities:
Short-term debt (Note 5)	412,600	83,400
Accounts payable	248,800	161,400
Employee compensation and benefits	152,100	148,700
Deferred revenue	93,600	19,000
Other current liabilities	373,100	317,900
Liabilities held-for-sale	0	1,700
Total current liabilities	1,280,200	732,100
Long-term debt	2,350,800	1,397,600
Deferred tax liabilities	149,900	24,100
Long-term tax payable	113,200	139,600
Deferred revenue	198,300	100
Accrued pension liability and other	225,200	370,700
Total liabilities	4,317,600	2,664,200
Contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $10 cents par value, 1.0 shares authorized, zero shares issued or outstanding	0	0
Common stock, $10 cents par value, 120.0 shares authorized, 53.8 issued and 49.3 outstanding at October 31, 2022 and 53.7 issued and 49.3 outstanding at October 31, 2021	5,400	5,400
Additional paid-in capital	1,765,500	1,715,200
Accumulated other comprehensive loss	(466,800)	(341,300)
Retained earnings	6,584,900	6,202,100
Treasury stock at cost: 4.5 shares at October 31, 2022 and 4.4 shares at October 31, 2021	(714,500)	(639,600)
Total Cooper stockholders' equity	7,174,500	6,941,800
Noncontrolling interests	200	200
Stockholders’ equity (Note 8)	7,174,700	6,942,000
Total liabilities and stockholders’ equity	$ 11,492,300	$ 9,606,200

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for credit losses	$ 20.7	$ 9.2
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, authorized (in shares)	1,000,000.0	1,000,000.0
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, authorized (in shares)	120,000,000.0	120,000,000.0
Common stock, issued (in shares)	53,800,000	53,700,000
Common stock, outstanding (in shares)	49,300,000	49,300,000
Treasury stock (in shares)	4,500,000	4,400,000

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Shares	Treasury Stock	Treasury Stock Par Net Value	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interests	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjustment Retained Earnings
Common stock, beginning balance (in shares) at Oct. 31, 2019		49,100,000
Treasury stock, beginning balance (in shares) at Oct. 31, 2019			4,100,000
Beginning balance at Oct. 31, 2019	$ 3,628.6	$ 4.9	$ (571.2)	$ 0.4	$ 1,615.0	$ (447.1)	$ 3,026.4	$ 0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	238.4						238.4
Other comprehensive income (loss), net of tax	(24.9)					(24.9)
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		200,000	1,700,000
Issuance of common stock for stock plans, net and employee stock purchase plan	(3.3)				(5.0)
Treasury stock repurchase (in shares)		200,000	200,000
Treasury stock repurchase	(47.8)		$ (47.8)
Dividends on common stock ($0.03 per share)	(3.0)						(3.0)
Share-based compensation expense	36.8				36.8
Common stock, ending balance (in shares) at Oct. 31, 2020		49,100,000
Treasury stock, ending balance (in shares) at Oct. 31, 2020			4,300,000
Ending balance at Oct. 31, 2020	$ 3,824.8	$ 4.9	$ (617.3)	0.4	1,646.8	(472.0)	3,261.8	0.2	$ (1.4)	$ (1.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2016-13 [Member]
Net income	$ 2,944.7						2,944.7
Other comprehensive income (loss), net of tax	130.7					130.7
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		300,000	2,500,000
Issuance of common stock for stock plans, net and employee stock purchase plan	$ 27.2	$ 0.1			24.6
Treasury stock repurchase (in shares)	69,622	100,000	100,000
Treasury stock repurchase	$ (24.8)		$ (24.8)
Dividends on common stock ($0.03 per share)	(3.0)						(3.0)
Share-based compensation expense	$ 43.8				43.8
Common stock, ending balance (in shares) at Oct. 31, 2021	49,300,000	49,300,000
Treasury stock, ending balance (in shares) at Oct. 31, 2021	4,400,000		4,400,000
Ending balance at Oct. 31, 2021	$ 6,942.0	$ 5.0	$ (639.6)	0.4	1,715.2	(341.3)	6,202.1	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	385.8						385.8
Other comprehensive income (loss), net of tax	(125.5)					(125.5)
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		100,000	3,600,000
Issuance of common stock for stock plans, net and employee stock purchase plan	$ 1.5				(2.1)
Treasury stock repurchase (in shares)	191,165	100,000	100,000
Treasury stock repurchase	$ (78.5)		$ (78.5)
Dividends on common stock ($0.03 per share)	(3.0)						(3.0)
Share-based compensation expense	$ 52.4				52.4
Common stock, ending balance (in shares) at Oct. 31, 2022	49,300,000	49,300,000
Treasury stock, ending balance (in shares) at Oct. 31, 2022	4,500,000		4,500,000
Ending balance at Oct. 31, 2022	$ 7,174.7	$ 5.0	$ (714.5)	$ 0.4	$ 1,765.5	$ (466.8)	$ 6,584.9	$ 0.2

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Statement of Stockholders' Equity [Abstract]
Dividends on common stock (in dollars per share)	$ 0.03	$ 0.03	$ 0.03

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Cash flows from operating activities:
Net income	$ 385.8	$ 2,944.7	$ 238.4
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	346.1	309.3	287.1
Impairment of intangibles	2.3	0.0	0.0
Share-based compensation expense	54.2	43.8	37.6
Non-cash operating lease expense	32.2	31.8	32.5
Impairment and loss on disposal of property, plant and equipment, and other	2.2	(5.0)	17.7
Change in fair value of contingent consideration	(10.3)	66.1	0.0
Deferred income taxes	53.9	(2,502.2)	(0.9)
Change in assets and liabilities:
Accounts receivable	(33.8)	(75.5)	8.5
Inventories	(40.4)	(9.2)	(62.3)
Other assets	(16.9)	(69.1)	(41.1)
Operating lease right-of-use assets and liabilities, net	(51.3)	(27.5)	(20.0)
Accounts payable	49.9	(16.0)	23.2
Accrued liabilities	32.4	59.1	(9.3)
Accrued income taxes	(27.4)	10.0	(12.4)
Other long-term liabilities	(34.2)	(21.7)	(12.4)
Settlement of contingent consideration	(52.3)	0.0	0.0
Net cash provided by operating activities	692.4	738.6	486.6
Cash flows from investing activities:
Purchases of property, plant and equipment	(242.0)	(214.4)	(310.4)
Acquisitions of businesses and assets, net of cash acquired	(1,641.3)	(235.9)	(54.1)
Proceeds from sale of interest in a subsidiary	52.1	0.0	0.0
Net cash used in investing activities	(1,831.2)	(450.3)	(364.5)
Cash flows from financing activities:
Proceeds from long-term debt, net of issuance costs	1,511.0	1,427.4	3,199.8
Repayments of long-term debt	(561.5)	(1,416.0)	(3,235.9)
Net proceeds from (repayments of) short-term debt, other	329.3	(321.3)	(4.5)
Repurchase of common stock	(78.5)	(24.8)	(47.8)
Proceeds related to share-based compensation awards	8.9	33.7	13.5
Payments related to share-based compensation awards	(16.8)	(13.2)	(20.3)
Dividends on common stock	(3.0)	(3.0)	(3.0)
Issuance of common stock for employee stock purchase plan	7.2	5.8	2.7
Settlement of contingent consideration	(2.9)	0.0	0.0
Net cash provided by (used in) financing activities	1,193.7	(311.4)	(95.5)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(12.9)	2.9	0.7
Net increase (decrease) in cash, cash equivalents and restricted cash	42.0	(20.2)	27.3
Cash, cash equivalents, restricted cash and cash held for sale at beginning of year	96.6	116.8	89.5
Cash, cash equivalents and restricted cash at end of year	138.6	96.6	116.8
Supplemental disclosures of cash flow information:
Interest	49.1	28.4	46.5
Income taxes	66.6	63.2	51.1
Operating lease liabilities	45.3	37.4	40.6
Operating lease ROU assets obtained in exchange for lease obligations	29.8	26.5	17.7
Reconciliation of cash flow information:
Cash and cash equivalents	138.2	95.9	115.9
Restricted cash included in other current assets	0.4	0.4	0.9
Cash held for sale	0.0	0.3	0.0
Total cash, cash equivalents, restricted cash and cash held for sale	$ 138.6	$ 96.6	$ 116.8

Organization and Significant Accounting Policies

12 Months Ended

Oct. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Significant Accounting Policies

Note 1. Organization and Significant Accounting Policies

Organization

The Cooper Companies, Inc. (Cooper, we or the Company) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical.

•CooperVision primarily develops, manufactures and markets a broad range of soft contact lenses for the worldwide vision correction market.

•CooperSurgical primarily develops, manufactures, markets medical devices and procedures solutions, and provides services to improve health care delivery to women, babies and families.

Principles of Consolidation

The financial statements in this report include the results of all of Cooper's consolidated entities. All significant intercompany transactions and balances are eliminated on consolidation.

Use of Estimates

The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates.

In particular, the COVID-19 pandemic negatively impacted business and healthcare activity globally. As a result of healthcare systems responding to the demands of managing the pandemic, governments around the world imposing measures designed to reduce the transmission of the COVID-19 virus, and individuals responding to the concerns of contracting the COVID-19 virus, many optical practitioners and retailers, hospitals, medical offices and fertility clinics closed their facilities, restricted access, or delayed or canceled patient visits, exams and elective medical procedures, and many customers that have reopened are experiencing reduced patient visits. These factors have had, and in the future may have, an adverse effect on our sales, operating results and cash flows.

The full extent to which the pandemic will directly or indirectly impact the Company's business, results of operations, and financial condition, including sales, expenses, manufacturing, clinical trials, research and development costs, reserves and allowances, fair value measurements, asset impairment charges, contingent consideration obligations, and the effectiveness of the Company's hedging instruments, will depend on future developments that are highly uncertain and difficult to predict. These developments include, but are not limited to, the duration and spread of the outbreak (including new and more contagious variants of COVID-19), its severity, the actions to contain the virus or address its impact, the timing, distribution, public acceptance and efficacy of vaccines and other treatments, United States and foreign government actions to respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume. There was not a material impact to the estimates in the Company’s Consolidated Financial Statements for fiscal 2022.

The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material changes to the estimates and material impacts to the Company’s Consolidated Financial Statements in future reporting periods.

Revenue recognition

Net Sales

The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers may subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.

Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note 12. Business Segment Information for disaggregation of revenue.

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liabilities. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently.

Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract.

Trade Discounts and Allowances

The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.

Product Returns

Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Historically, returns have been infrequent and insignificant relative to our total sales. Our refund liability for product returns was $14.5 million and $13.7 million at October 31, 2022 and 2021, respectively, which is included in Accrued Liabilities on our Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers.

Rebates and Chargebacks

Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served.

Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical products in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis.

Contract Liabilities

Deferred revenue primarily represents prepaid stem cell storage as part of the CooperSurgical business unit. Revenue related to stem cell storage is recognized over the service period, which can range from one year to the lifetime of a customer.

Share-Based Compensation

We grant various share-based compensation awards, including stock options, performance unit shares, restricted stock and restricted stock units. The Company accounts for share-based compensation expense based on estimated grant-date fair value, and expenses the amount over the vesting period of the award. Determining the fair value of share-based awards at the grant date requires judgment, including estimating Cooper's stock price volatility, employee exercise behaviors and related employee forfeiture rates.

The expected life of the share-based awards is based on the observed and expected time to post-vesting forfeiture and/or exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. In determining the expected volatility, management considers implied volatility from publicly-traded options on Cooper's common stock at the date of grant, historical volatility and other factors. The risk-free interest rate is based on the continuous rates provided by the United States Treasury with a term equal to the expected life of the award. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant.

Forfeitures are estimated at the time of grant, based on historical experience, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Foreign Currency Translation

Most of our operations outside the United States use their local currency as their functional currency. We translate these assets and liabilities into United States dollars at year-end exchange rates. We translate income and expense accounts at average rates for each month. We record gains and losses from the translation of financial statements in foreign currencies into United States dollars in other comprehensive income. We record gains and losses from changes in exchange rates on transactions denominated in currencies other than each reporting location's functional currency in net income for each period. We recorded in other expense and income a net foreign exchange loss of $22.0 million for fiscal 2022, $5.5 million for fiscal 2021 and $1.2 million for fiscal 2020.

Financial Derivatives and Hedging

Derivatives are recorded on the Consolidation Balance Sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.

The gain or loss on derivative instruments designated and qualifying for cash flow hedge accounting is deferred in other comprehensive income. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. Deferred gains or losses from designated cash flow hedges are reclassified into earnings in the period that the hedged interest expense affects earnings. The effectiveness of cash flow hedges is assessed at inception and quarterly thereafter. The Company does not offset fair value amounts recognized for derivative instruments in its Consolidated Balance Sheets for presentation purposes.

Fair Value Measurements

Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

The carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms.

The carrying value of the Company's revolving credit facility and term loans approximates fair value based on current market rates (Level 2).

The fair value of the Company's interest rate swap contracts is measured on a recurring basis by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates (forward curves) derived from observable market interest rate curves. The interest rate swap contracts were categorized as Level 2 in the fair value hierarchy, as the inputs to the derivative pricing model are generally observable and do not contain a high level of subjectivity. The gain or loss on the derivatives is recorded as a component of accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Refer to Note 13. Financial Derivatives and Hedging for further information.

The Company uses fair value measures when determining assets and liabilities acquired in an acquisition, which are considered a Level 3 measurement. The fair value of the Company's contingent consideration for which a liability is recorded and the initial measurement of the joint venture interest are a Level 3 measurement, and the change in fair value is recognized in selling,

general and administrative expense in the Consolidated Statements of Income. Refer to Note 3. Acquisitions and Joint Venture for further information.

Income taxes

Income taxes are estimated based on enacted income tax laws and the results of operations in each jurisdiction. Deferred tax assets and liabilities are estimated based on temporary differences between the financial reporting basis and income tax basis of assets and liabilities. Deferred tax assets are also estimated based on net operating loss and tax credit carryforwards. Deferred tax assets are reduced by a valuation allowance to the extent it is more likely than not they are not expected to be realized. Adjustments to deferred tax assets and liabilities due to changes in tax laws, changes in jurisdiction from intra-group transfers of assets, and changes in judgment regarding a valuation allowance are recognized in provision for income taxes in the quarter in which such changes occur. Long-term tax payable is estimated income tax to be paid for unrecognized tax benefits. A tax benefit is recognized if it is more likely than not a tax position will be sustained based on its technical merits in a tax authority examination, based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. Adjustments to unrecognized tax benefits due to changes in judgment are recognized in provision for income taxes in the quarter in which such changes occur. Interest and penalties related to unrecognized tax benefits are recognized in provision for income taxes.

Earnings Per Share

We determine basic earnings per share (EPS) by using the weighted average number of shares outstanding. We determine diluted EPS by increasing the weighted average number of shares outstanding in the denominator by the number of outstanding dilutive equity awards using the treasury stock method.

Cash and Cash Equivalents

The Company considers all short-term, highly liquid investments purchased with maturities of three months or less to be cash equivalents.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.


October 31, (In millions)	2022		2021
Raw materials	$	173.7	$	137.7
Work-in-process	15.2		14.0
Finished goods	439.8		433.9
	$	628.7	$	585.6

In assessing the value of inventories, we make estimates and judgments regarding aging of inventories and other relevant issues potentially affecting the salable condition of products and estimated prices at which those products will sell. On an ongoing basis, we review the carrying value of our inventory, measuring number of months on hand and other indications of salability. We reduce the value of inventory if there are indications that the carrying value is greater than net realizable value, resulting in a new, lower-cost basis for that inventory. Subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. While estimates are involved, historically, obsolescence has not been a significant factor due to long product dating and lengthy product life cycles.

Property, Plant and Equipment

We record property, plant, and equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally 3 to 15 years except for buildings which are depreciated over 30 to 40 years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.


October 31, (In millions)	2022		2021
Land and improvements	$	18.7	$	20.3
Buildings and improvements	415.6		388.0
Machinery and equipment	1,973.6		1,863.6
Construction in progress	393.0		383.8
Property, plant and equipment, at cost	$	2,800.9	$	2,655.7
Less: Accumulated depreciation	1,387.2		1,308.1
Property, plant and equipment, net	$	1,413.7	$	1,347.6
Finance lease ROU assets, net	19.2		—
	$	1,432.9	$	1,347.6

Leases

We consider an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. We have operating leases, but do not have material financing leases. The Company primarily has operating leases for office, manufacturing and warehouse space, vehicles, and office equipment.

Lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the future minimum lease payments over the lease term. The lease term reflects the noncancellable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. Changes in the lease term assumption could impact the right-of-use assets and lease liabilities recognized on the Consolidated Balance Sheets. As our leases typically do not contain a readily determinable implicit rate, we determine the present value of the lease liability using our incremental borrowing rate at the lease commencement date based on the lease term on a collateralized basis.

The Company’s operating leases typically include non-lease components such as common-area maintenance costs. The Company has elected to include non-lease components with lease payments for the purpose of calculating lease right-of-use assets and liabilities, to the extent that they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments.

Leases with a term of one year or less are not recognized on the Consolidated Balance Sheets, while the associated lease payments are expensed in the Consolidated Statements of Income and Comprehensive Income on a straight-line basis over the lease term.

Operating leases are classified in “Other current liabilities”, “Accrued pension liability and other”, and “Other assets” on our consolidated balance sheets. Operating lease expense is recognized on a straight-line basis over the expected lease term and included in selling, general and administrative expenses in the Consolidated Statements of Income. Financing leases are classified in "Property, plant and equipment", "Short-term debt", and "Long-term debt" on our consolidated balance sheets. See Note 2. Operating Leases and Note 5. Financing Arrangements for further information.

Cloud Computing Arrangements

The Company capitalizes certain costs related to the acquisition and development of internal use software, including implementation costs incurred in a cloud computing arrangement, during the application development stages of projects. Capitalized implementation costs are amortized on a straight-line basis over the expected term of the hosting arrangement, which includes consideration of the non-cancellable contractual term and reasonably certain renewals. Costs incurred during the preliminary project or the post-implementation/operation stages of the project are expensed as incurred. Implementation costs are included in “Other assets” in the Consolidated Balance Sheets. Amortization of capitalized implementation costs is included in the same line item in the Consolidated Statements of Income as the expense for fees for the associated hosting arrangement.

Valuation of goodwill

We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. Goodwill is tested for impairment at the reporting unit level by performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. We perform a qualitative assessment to test each reporting unit's goodwill for impairment, which

includes industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value of the reporting unit.

Long-lived Assets

We review long-lived assets held and used, intangible assets with definite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset group are compared to the asset group's carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value. If management has committed to a plan to dispose of long-lived assets, the assets to be disposed of are reported at the lower of carrying amount or fair value less estimated costs to sell.

Indefinite-lived Intangible Assets

We assess indefinite-lived intangible assets annually in the third quarter of the fiscal year, or whenever events or changes in circumstances indicate that the carrying amount of an indefinite-lived intangible asset (asset group) may not be recoverable. We evaluate whether the indefinite-lived intangible asset is impaired by comparing its carrying value to its fair value. If the carrying value of an indefinite-lived intangible asset is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value.

Business combinations

We routinely consummate business combinations. Results of operations for acquired companies are included in our consolidated results of operations from the date of acquisition. We recognize separately from goodwill, the identifiable assets acquired, including acquired in-process research and development, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date fair values as defined by accounting standards related to fair value measurements. Key assumptions routinely utilized in allocation of purchase price to intangible assets include discount rates and projected financial information such as revenue projections for companies acquired. As of the acquisition date, goodwill is measured as the excess of consideration given, over the net of the acquisition date fair values of the identifiable assets acquired and the liabilities assumed. Direct acquisition costs are expensed as incurred.

Litigation

We are subject to various legal proceedings, claims, litigation, investigations and contingencies arising out of the ordinary course of business. If we believe the likelihood of an adverse legal outcome is probable and the amount is estimable, we accrue a liability in accordance with accounting guidance for contingencies. We consult with legal counsel on matters related to litigation and seek input both within and outside the Company.

Treasury Stock

We record treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.

Exit costs

During the second quarter of fiscal 2022, the Company initiated a plan to exit its contact lens care business, a non-core business unit of the CooperVision segment. We expect the exit activity to be substantially completed in the first half of fiscal 2023. Exit charges recognized in the three and twelve months ended October 31, 2022, were $9.2 million and $33.2 million, of which $26.7 million is recognized in cost of sales and $6.5 million is recognized in selling, general, and administrative expense in the Consolidated Statements of Income. Exit costs primarily related to inventory write-down, asset impairments and employee-related costs. Total exit costs are expected to be in a range of $30.0 million to $40.0 million.

Accounting Pronouncements Recently Adopted

On November 1, 2021, we prospectively adopted ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers to the business combinations entered into during fiscal 2022. This update requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers.

Accounting Pronouncements Issued Not Yet Adopted

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-04 on the Consolidated Condensed Financial Statements.

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard is effective for fiscal years beginning after December 15, 2021, and should be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2021-10 on the Consolidated Condensed Financial Statements.

No other recently issued accounting pronouncements had or are expected to have a material impact on our Consolidated Financial Statements.

Operating Leases

12 Months Ended

Oct. 31, 2022

Leases [Abstract]

Operating Leases

Note 2. Operating Leases

The following table presents information about leases on the Consolidated Balance Sheets:


October 31, (In millions)	2022		2021
Operating Leases
Operating lease right-of-use assets	$	230.1	$	257.0

Operating lease liabilities, current	35.5		35.7
Operating lease liabilities, non-current	205.5		231.7
Total operating lease liabilities	$	241.0	$	267.4

Weighted average remaining lease term (in years)	9.8		10.6
Weighted average discount rate	3%		3%

Operating lease expense for the fiscal years ended October 31, 2022, 2021 and 2020 was $45.0 million, $44.1 million and $41.2 million.

Maturity of Lease Liabilities

The minimum rental payments required under operating leases that have initial or remaining noncancellable lease terms in excess of one year as of October 31, 2022 are:


(In millions)
2023	$	42.2
2024	36.6
2025	32.8
2026	30.2
2027	26.6
Thereafter	115.8
Total lease payments	$	284.2
Less: interest	43.2
Present value of lease liabilities	$	241.0

Acquisitions and Joint Venture

12 Months Ended

Oct. 31, 2022

Business Combination and Asset Acquisition [Abstract]

Acquisitions and Joint Venture

Note 3. Acquisitions and Joint Venture

The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2022, 2021, and 2020:


(In millions)	2022		2021		2020
Technology	$	1.9	$	178.6	$	—
In-Process Research & Development (IPR&D)	—		20.0		—
Customer relationships	729.2		7.5		11.4
Trademarks	55.4		1.3		5.1
Other	—		0.6		3.9
Total identifiable intangible assets	$	786.5	$	208.0	$	20.4

Goodwill	1,184.8		91.6		15.3
Net tangible liabilities	(286.5)		(10.8)		(0.3)
Fair value of contingent consideration	(1.5)		(39.1)		—
Total closing purchase price	$	1,683.3	$	249.7	$	35.4

All acquisitions were funded by cash generated from operations or facility borrowings.

For business acquisitions, the Company recorded tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition. For asset acquisitions, the Company recorded tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition.

The Company believes these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new distributors or complementary products and services.

Fiscal Year 2022

On May 31, 2022, CooperVision completed the acquisition of a privately-held Denmark-based contact lens distributor focusing on orthokeratology and scleral contact lenses. This acquisition expands CooperVision's ortho-k eye care portfolio in the Nordic market.

On April 6, 2022, CooperSurgical completed the acquisition of a private cryopreservation services company that specializes in cryogenic services. The purchase price allocation is preliminary, and the Company is in the process of finalizing information primarily related to the effect on taxes and the corresponding impact on goodwill.

Refer to "Fiscal Year 2021" below for details on formation of a joint venture with Essilor International and related activities that occurred in fiscal year 2022 following the acquisition of SightGlass Vision, Inc. (SGV) in fiscal year 2021.

On April 6, 2022, CooperSurgical entered into an asset purchase agreement to acquire Cook Medical's Reproductive Health business, a manufacturer of minimally invasive medical devices focused on the fertility, obstetrics and gynecology markets. The aggregate consideration is $875.0 million in cash, with $675.0 million payable at the closing and the remaining $200.0 million payable in $50.0 million installments following each of the first, second, third and fourth anniversaries of the closing. The transaction is subject to customary closing conditions, such as receipt of required regulatory approvals.

Generate Life Sciences®

On December 17, 2021, CooperSurgical completed the acquisition of 100% of the equity interests in Generate Life Sciences (Generate), a privately held leading provider of donor egg and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage (cord blood & cord tissue), and paid an aggregate purchase consideration of approximately $1.663 billion, reflecting working capital, and other adjustments. The cash consideration was funded through a combination of $1.5 billion in proceeds from the issuance of a senior unsecured term loan and available cash on hand.

The Company has accounted for the acquisition of Generate as a business combination, in accordance with ASC Topic 805, Business Combinations. The following table summarizes the preliminary fair values of assets acquired and liabilities assumed as of the acquisition date:


(In millions)
Current assets:
Cash and cash equivalents	$	58.6
Trade accounts receivable, net	18.1
Inventories	3.3
Prepaid expense and other current assets	33.5
Total current assets	113.5
Property, plant and equipment	42.6

Goodwill	1,177.3
Customer relationships	718.3
Trademarks	54.9

Other assets	21.5
Total assets acquired	$	2,128.1

Current liabilities:
Accounts payable	$	12.6
Employee compensation and benefits	12.3

Deferred revenue	68.0
Other current liabilities	12.4
Total current liabilities	105.3
Deferred tax liabilities	147.3

Lease liabilities	16.6
Deferred revenue	192.2

Other long-term liabilities	3.6
Total liabilities assumed	$	465.0

Total purchase price	$	1,663.1

The Company is in the process of finalizing purchase accounting information primarily related to deferred tax adjustments and the corresponding impact on goodwill. The Company recorded measurement period adjustments of $115.3 million to goodwill in fiscal 2022.

Deferred revenue was recognized in accordance with ASC Topic 606, Revenue from Contracts with Customers, as a result of the adoption of ASU 2021-08. See Note 1. Organization and Significant Accounting Policies for additional information.

The Company currently estimates that customer relationships will be amortized over 20 years and trademarks will be amortized over 15 years. Goodwill is primarily attributable to assembled workforce and expected synergies to be achieved. The goodwill recognized is not deductible for tax purposes.

The transaction costs associated with the acquisition consisted primarily of legal, regulatory and financial advisory fees, which were expensed as incurred as selling, general and administrative expense.

Generate's revenue and net income for the period from the acquisition date to October 31, 2022, were $249.5 million and $27.8 million, respectively. The following unaudited pro forma information summarizes the combined results of operations of the Company and Generate as if the acquisition had been completed at the beginning of the Company’s fiscal 2021:


(In millions)	2022		2021
Revenue	$	3,344.3	$	3,183.2
Net income	$	370.7	$	2,959.8

The unaudited pro forma information for fiscal 2022 and 2021 was calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments. The adjustments primarily include increased amortization for the fair value of acquired intangible assets, increased depreciation for the fair value of acquired property, plant, and equipment,

increased revenue as a result of the ASU 2021-08 deferred revenue adjustments, decreased interest expense as a result of the reversal of Generate's historical interest expense partially offset by additional interest expense on the debt obtained to finance the transaction.

The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred at the beginning of fiscal 2021, or of future results of the consolidated entities.

Subsequent Event

On November 1, 2022, subsequent to the fiscal year ended October 31, 2022, CooperVision closed an Agreement and Plan of Merger (the “Merger Agreement”) to acquire a U.S. based privately held leading expert in specialty contact lenses for both normal and irregular corneal conditions. The Company is in the process of finalizing purchase accounting information.

Fiscal Year 2021

On May 3, 2021, CooperSurgical completed the acquisition of a privately-held medical device company that develops single-use illuminating medical devices.

On April 26, 2021, CooperVision completed the acquisition of a privately-held UK contact lens manufacturer focusing on specialty contact lenses. This acquisition expands CooperVision’s specialty eye care portfolio and accelerates its development of myopia management solutions in the UK.

On March 1, 2021, CooperSurgical completed the acquisition of a privately-held medical device company that designed and developed an innovative obstetric product for use in urgent obstetrics to reduce risks associated with childbirth.

On February 1, 2021, CooperSurgical acquired all of the remaining equity interests of a privately-held medical device company that developed the Mara® Water Vapor Ablation System, which is used for endometrial ablation. The Company accounted for this acquisition as an asset acquisition, whereby the Company allocated the total cost of the acquisition to the net assets acquired on the basis of their estimated relative fair values on the acquisition date with no goodwill recognized. The primary asset acquired in this asset acquisition is Technology.

On January 19, 2021, CooperVision acquired all of the remaining equity interests of SGV, a privately-held medical device company that developed spectacle lenses for myopia management. The transaction included potential payments of future consideration that were contingent upon the achievement of the regulatory approval milestone (the regulatory approval payment) and the acquired business reaching certain revenue thresholds over a specified period (the revenue payments). The undiscounted range of the contingent consideration was zero to $139.1 million payable to the other former equity interest owners.

The fair value of the regulatory approval payment was determined using an option pricing framework based on the expected payment under the contractual terms and the estimates of the probability of achieving the regulatory approval. The fair value of the revenue payments was determined using a Monte Carlo simulation based on the revenue projections and the expected payment for each simulation.

In March 2022, the entities amended the terms of the contingent consideration, which resulted in CooperVision paying $42.9 million to the former equity interest owners in exchange for the elimination of the revenue payments. CooperVision recognized a net gain of $12.2 million during fiscal 2022. As of October 31, 2022, the remaining contingent liability related to regulatory approval payment was $31.8 million.

In March 2022, CooperVision and Essilor International SAS (Essilor) entered into a Contribution Agreement and a Stock Purchase Agreement under which Essilor paid CooperVision $52.1 million in exchange for a 50% interest in SGV and a proportionate share of certain revenue-based milestone payments related to the January 2021 acquisition of SGV by CooperVision. As part of these agreements, each party contributed their interest in SGV and $10 million in cash to form a new joint venture. CooperVision then remeasured the fair value of its retained equity investment in the joint venture at $90.0 million which resulted in a $56.9 million gain in Other (income) expense on deconsolidation of SGV.

The fair value of the joint venture was determined using the income valuation approach. Under the income approach, we used a discounted cash flow model (“DCF”) in which cash flows anticipated over several periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate expected rate of return. The discount rate used for cash flows reflects capital market conditions and the specific risks associated with the business. This valuation approaches is considered a Level 3 fair value measurement. Fair value determination requires complex assumptions and judgment by management in projecting future operating results, selecting guideline companies for comparisons, determining appropriate

market value multiples, selecting the discount rate to measure the risks inherent in the future cash flows. Any material changes in key assumptions, including failure to meet business plans, deterioration in the financial market, an increase in interest rate or an increase in the cost of equity financing by market participants within the industry or other unanticipated events and circumstances, may affect such estimates.

On December 31, 2020, CooperSurgical completed the acquisition of a privately-held in vitro fertilization (IVF) cryostorage software solutions company.

The pro forma results of operations of these acquisitions have not been presented because the effect of the business combinations described above was not material to the consolidated results of operations.

Fiscal Year 2020

On August 7, 2020, CooperVision completed the acquisition of a privately-held U.S contact lens manufacturer focusing on ortho-k lenses. This acquisition expands CooperVision’s specialty eye care portfolio and its leadership in addressing the increasing severity and prevalence of myopia.

On December 13, 2019, CooperSurgical completed the acquisition of a privately-held distributor of IVF medical devices and systems.

Contingent Consideration

Certain of the Company’s business combinations involve potential payments of future consideration that are contingent upon the achievement of regulatory milestones and/or the acquired business reaching certain revenue thresholds. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized in selling, general and administrative expense in the Consolidated Statements of Income.

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:


(In millions)	2022		2021
Beginning balance	$	97.4	$	—
Purchase price contingent consideration	1.5		31.3
Payments	(55.2)		—
Change in fair value	(10.3)		66.1
Ending balance	$	33.4	$	97.4

Intangible Assets

12 Months Ended

Oct. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 4. Intangible Assets

Goodwill

The Company has three reporting units: CooperVision and within the CooperSurgical segment, Office/Surgical and Fertility, reflecting the current way the Company manages its business. There was no impairment of goodwill in its reporting units in fiscal 2022, 2021, and 2020.


(In millions)	CooperVision		CooperSurgical		Total




Balance at October 31, 2021	$	1,841.0	$	733.0	$	2,574.0
Net additions	0.9		1,183.9		1,184.8

Foreign currency translation adjustment	(131.6)		(17.5)		(149.1)
Balance at October 31, 2022	$	1,710.3	$	1,899.4	$	3,609.7

Of the October 31, 2022 goodwill balance, $214.1 million for CooperSurgical and $22.4 million for CooperVision is expected to be deductible for tax purposes. Of the October 31, 2021 goodwill balance, $137.2 million for CooperSurgical and $24.6 million for CooperVision was expected to be deductible for tax purposes.

Other Intangible Assets


	October 31, 2022				October 31, 2021
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted Average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	209.6	$	62.4	$	156.7	$	49.1	15
Composite intangible asset	1,061.9		354.0		1,061.8		283.2		15
Technology	504.1		317.5		513.0		287.9		12
Customer relationships	1,092.7		287.0		378.4		240.1		19
License and distribution rights and other	50.7		23.8		33.4		21.6		11
	2,919.0		$	1,044.7	2,143.3		$	881.9	16
Less: accumulated amortization and translation	1,044.7				881.9
Intangible assets with definite lives, net	$	1,874.3			$	1,261.4
Intangible assets with indefinite lives, net (1)	10.8				10.1
Total other intangibles, net	$	1,885.1			$	1,271.5

(1) Intangible assets with indefinite lives include technology and trademarks.

Balances include foreign currency translation adjustments.

Intangible assets with definite lives are amortized over the estimated useful life of the assets. As of October 31, 2022, the estimate of future amortization expenses for intangible assets with definite lives is as follows:


Fiscal years:	(In millions)
2023	$	183.2
2024	179.2
2025	169.3
2026	162.0
Thereafter	1,180.6
Total remaining amortization for intangible assets with definite lives	$	1,874.3

The Company considered the impact on its near and long-term forecasts from the general deterioration of economic and market conditions as a result of higher inflation, regional and global conflict, supply chain disruption, and the ongoing disruptions of the COVID-19 pandemic and determined that it was not more likely than not that the fair value of reporting units or relevant asset groups was below carrying amounts. Therefore, the Company determined that there was no impairment to either its definite-lived or indefinite-lived intangible assets during fiscal 2022, 2021 and 2020. There was an immaterial impairment charge related to our exit from the contact lens care business.

Financing Arrangements

12 Months Ended

Oct. 31, 2022

Debt Disclosure [Abstract]

Financing Arrangements

Note 5. Financing Arrangements

The Company had outstanding debt as follows:


October 31, (In millions)	2022		2021


Overdraft and other credit facilities	$	57.7	$	83.0
Term loans	338.0		—
Less: unamortized debt issuance cost	—		(0.1)
Short-term debt, excluding financing leases	395.7		82.9
Financing lease liabilities	16.9		0.5
Short-term debt	$	412.6	$	83.4

Revolving credit	$	—	$	546.1
Term loans	2,350.0		850.0
Other	0.2		0.2
Less: unamortized debt issuance cost	(3.1)		(0.2)
Long-term debt, excluding financing leases	2,347.1		1,396.1

Financing lease liabilities	3.7		1.5
Long-term debt	$	2,350.8	$	1,397.6
Total debt	$	2,763.4	$	1,481.0

As of October 31, 2022, the Company was in compliance with all debt covenants.

Term Loan Agreement on December 17, 2021

On December 17, 2021, the Company entered into a Term Loan Agreement (the 2021 Credit Agreement) by and among the Company, the lenders from time to time party thereto, and PNC Bank, National Association, as administrative agent. The 2021 Credit Agreement provides for a term loan facility (the 2021 Term Loan Facility) in an aggregate principal amount of $1.5 billion, which, unless terminated earlier, matures on December 17, 2026. In addition, the Company has the ability from time to time to request an increase to the commitments under the 2021 Term Loan Facility or to establish a new term loan facility under the 2021 Credit Agreement in an aggregate principal amount not to exceed $1.125 billion, upon prior written notice to the administrative agent and subject to the discretionary participation of the lenders funding such term loans and certain limitations set forth in the 2021 Credit Agreement.

Amounts outstanding under the 2021 Term Loan Facility will bear interest, at the Company’s option, at either (i) the alternate base rate, which is a rate per annum equal to the greatest of (a) the administrative agent’s prime rate, (b) one-half of one percent in excess of the federal funds effective rate and (c) one percent in excess of the adjusted London interbank offered rate (“LIBOR”) for a one-month interest period on such day, or (ii) the adjusted LIBOR, plus, in each case, an applicable rate of, initially, zero basis points, in respect of base rate loans, and 75 basis points, in respect of adjusted LIBOR loans. Following a specified period after the closing date, the applicable rates will be determined quarterly by reference to a grid based upon the Company’s ratio of consolidated net indebtedness to consolidated EBITDA, each as defined in the 2021 Credit Agreement.

The Company may prepay loan balances from time to time, in whole or in part, without premium or penalty (other than any related breakage costs).

On December 17, 2021, the Company borrowed $1.5 billion under the 2021 Term Loan Facility and used the proceeds to fund the acquisition of Generate. Refer to Note 3. Acquisitions and Joint Venture for more details.

The interest rate on the 2021 Term Loan Facility was 4.44% at October 31, 2022.

The 2021 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the 2021 Credit Agreement, consistent with the 2020 Credit Agreement discussed below.

Term Loan Agreement on November 2, 2021

On November 2, 2021, the Company entered into a 364-day, $840.0 million, term loan agreement by and among the Company, the lenders party thereto and The Bank of Nova Scotia, as administrative agent, which matured subsequent to year end on November 1, 2022. The Company used part of the funds to partially repay outstanding borrowings under the 2020 Revolving Credit Facility and for general corporate purposes.

We repaid $502.0 million during fiscal 2022. Amounts outstanding under the 2021 364-Day Term Loan Agreement will bear interest, at the Company’s option, at either the alternate base rate, or the adjusted LIBOR (each as defined in the 2021 364-Day Term Loan Agreement), plus, in the case of adjusted LIBOR loans, an applicable rate of 60 basis points.

The 2021 364-Day Term Loan Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain total leverage ratio and interest coverage ratio, each as defined in the 2021 364-Day Term Loan Agreement, consistent with the 2020 Credit Agreement discussed below.

Revolving Credit and Term Loan Agreement on April 1, 2020

On April 1, 2020, the Company entered into a Revolving Credit and Term Loan Agreement (the 2020 Credit Agreement), among the Company, CooperVision International Holding Company, LP, CooperSurgical Netherlands B.V., CooperVision Holding Kft. the lenders from time to time party thereto, and KeyBank National Association, as administrative agent. The 2020 Credit Agreement provides for (a) a multicurrency revolving credit facility (the 2020 Revolving Credit Facility) in an aggregate principal amount of $1.29 billion and (b) a term loan facility (the 2020 Term Loan Facility) in an aggregate principal amount of $850.0 million, each of which, unless terminated earlier, mature on April 1, 2025. The Company used $850.0 million under the 2020 Term Loan Facility and $445.0 million under the 2020 Revolving Credit Facility to fully repay all borrowings outstanding under a previously existing term loan agreement and transfer all letters of credit and borrowings outstanding under a previously existing credit agreement to the 2020 Credit Agreement. The Company has an uncommitted option to increase the revolving credit facility or establish a new term loan in an aggregate amount up to $1.605 billion.

On October 30, 2020, the Company entered into Amendment No. 1 to the 2020 Credit Agreement, adding CooperVision International Limited as a revolving borrower and releasing certain borrowers in the 2020 Credit Agreement.

On December 17, 2021, the Company entered into Amendment No.2 to the 2020 Credit Agreement, modifying the 2020 Credit Agreement by, among other things, adding CooperSurgical Holdings Limited as a revolving borrower, releasing CooperVision Holding Kft as a borrower, and updating the benchmark replacement language in the 2020 Credit Agreement.

The 2020 Credit Agreement will bear interest, at the Company’s option, at either the base rate, or the adjusted LIBOR or adjusted foreign currency rate, plus, in each case, an applicable rate of between 0.00% and 0.50% in respect of base rate loans, and between 0.75% and 1.50% in respect of adjusted LIBOR or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2020 Credit Agreement. The Company may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reduction of the revolving commitment.

The Company pays an annual commitment fee that ranges from 0.10% to 0.20% of the unused portion of the 2020 Revolving Credit Facility based upon the Company’s Total Leverage Ratio, as defined in the 2020 Credit Agreement.

At October 31, 2022, the Company had $850.0 million outstanding under the 2020 Term Loan Facility and none outstanding under the 2020 Revolving Credit Facility. The interest rate on the 2020 Term Loan Facility was 4.13% at October 31, 2022. The interest rate on the 2020 Revolving Credit Facility was 4.13% at October 31, 2022.

Payments on the outstanding long-term debt balance of $850.0 million are due in the fiscal year ending October 31, 2025.

European and Asian Pacific Credit Facilities

The Company maintains European credit facilities. The aggregate facility limit was $30.7 million and $35.8 million at October 31, 2022 and 2021, respectively. At October 31, 2022, $12.3 million of the facilities was utilized and the weighted average interest rate on the outstanding balances was 2.46%.

The Company maintains Yen-denominated credit facilities in Japan. The aggregate facility limit was $73.0 million and $95.0 million at October 31, 2022 and 2021, respectively. At October 31, 2022, $45.4 million of the combined facilities was utilized and the weighted average interest rate on the outstanding balances was 0.40%.

Each facility is supported by a continuing and unconditional guaranty.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Income Taxes

12 Months Ended

Oct. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

Note 6. Income Taxes

Effective Tax Rate

The effective tax rates for fiscal 2022 and 2021 were 18.8% and (499.1)%, respectively. The increase was primarily due to an intra-group transfer of intellectual property in fiscal 2021 and UK tax rate change in fiscal 2021, as discussed below. The increase was also due to changes in the geographic composition of pre-tax earnings and changes in excess tax benefits from share-based compensation.

The effective tax rate for fiscal 2022 was lower than the US federal statutory rate primarily due to foreign earnings in jurisdictions with lower tax rates and changes in unrecognized tax benefits, partially offset by foreign earnings subject to US tax. The effective tax rate for fiscal 2021 was lower than the US federal statutory tax rate primarily due to the intra-group transfer, UK tax rate change, and earnings in foreign jurisdictions with lower tax rates partially offset by foreign earnings subject to US tax.

In November 2020, the Company completed an intra-group transfer of certain intellectual property and related assets of CooperVision to a UK subsidiary as part of a group restructuring to establish headquarters operations in the UK. Determining fair value involved significant judgment related to future revenue growth, operating margins, and discount rates. The transfer resulted in a step-up of the UK tax-deductible basis in the intellectual property and goodwill, creating a temporary difference between the book basis and the tax basis of these assets. As a result, the Company recognized a deferred tax asset of $1,987.9 million, with a corresponding income tax benefit, during the first quarter of fiscal 2021. During the third quarter of fiscal 2021, the Company recognized a $536.7 million tax benefit related primarily to the remeasurement of this deferred tax asset caused by the UK enactment of a 25% corporate tax rate.

Components of income before income taxes:


Years Ended October 31, (In millions)	2022		2021		2020
Income before income taxes:
United States	$	31.4	$	(31.0)	$	(88.0)
Foreign	443.9		522.5		354.5
	$	475.3	$	491.5	$	266.5

Components of provision for income taxes:


Years Ended October 31, (In millions)	2022		2021		2020
Current:
Federal	$	10.2	$	21.0	$	1.4
State	3.8		1.3		1.1
Foreign	21.7		26.7		26.5
	35.7		49.0		29.0

Deferred:
Federal	10.5		(8.8)		3.2
State	(2.2)		(0.5)		0.8
Foreign	45.6		(2,492.9)		(4.9)
	53.9		(2,502.2)		(0.9)
Provision for income taxes	$	89.5	$	(2,453.2)	$	28.1

Reconciliation between the expected provision for income taxes at the US federal statutory rate and the provision for income taxes:


Years Ended October 31, (In millions)	2022		2021		2020
Provision for income taxes at United States statutory tax rate	$	99.8	$	103.2	$	56.0
(Decrease) increase in taxes resulting from:
Foreign earnings in jurisdictions with lower tax rates	(22.3)		(43.6)		(54.7)
Foreign earnings subject to United States tax	20.7		25.4		32.0

Excess tax benefits from share-based compensation	(2.6)		(13.0)		(6.2)
Deferred tax asset step-up	(3.4)		3.2		(9.0)
United States provision-to-return	0.5		(1.2)		7.0
Intra-group transfer to UK subsidiary	—		(1,987.8)		—
Remeasurement of deferred tax assets from UK rate change	—		(536.7)		—
Change in unrecognized tax benefits	(12.7)		(7.6)		(0.1)
State tax provision	5.0		0.8		1.9
Other, net	4.5		4.1		1.2
Provision for income taxes	$	89.5	$	(2,453.2)	$	28.1

Components of deferred tax assets and liabilities:


Years Ended October 31, (In millions)	2022		2021
Deferred tax assets:
Accounts receivable	$	4.9	$	3.4
Inventories	6.3		6.1
Accrued liabilities, reserves and compensation accruals	79.9		78.1
Foreign deferred tax assets	2,500.5		2,531.5
Share-based compensation	14.5		28.6
Net operating loss and tax credit carryforwards	19.6		19.3
Intangible assets	—		6.8
Capitalized research and experimental expenses	15.4		13.5
Total gross deferred tax assets	2,641.1		2,687.3
Less: valuation allowance	(60.1)		(51.8)
Deferred tax assets	2,581.0		2,635.5
Deferred tax liabilities:
Tax deductible goodwill	(39.7)		(34.0)
Intangible assets	(153.8)		—
Plant and equipment	(48.8)		(46.5)
Foreign deferred tax liabilities	(45.5)		(32.5)


Total gross deferred tax liabilities	(287.8)		(113.0)
Net deferred tax assets	$	2,293.2	$	2,522.5

In assessing the realizability of deferred tax assets, the Company analyzes whether some or all deferred tax assets will not be realized. This analysis considers historical taxable income, the projected reversal of deferred tax liabilities, projected taxable income and tax planning strategies. Based upon this analysis, it is more likely than not the deferred tax assets, net of valuation allowance, will be realized. The increase in valuation allowance is primarily related to foreign tax attributes.

At October 31, 2022, the Company had federal net operating loss carryforwards of $65.4 million and state net operating loss carryforwards of $97.3 million. Federal net operating loss carryforwards of $17.1 million expire on various dates between 2025 and 2037 and $48.3 million do not expire. The state net operating loss carryforwards expire on various dates between 2026 through 2042.

A tax benefit is recognized if it is more likely than not that a tax position will be sustained on its technical merits, based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority.

Changes in unrecognized tax benefits:


(In millions)
Balance at October 31, 2020	$	58.5
Decrease based on tax positions in prior fiscal years	(8.3)
Increase based on tax positions in current fiscal year	307.2
Settlements	(1.9)
Lapses of statutes of limitations	(1.7)
Balance at October 31, 2021	$	353.8
Decrease based on tax positions in prior fiscal years	(12.5)

Settlements	(0.2)

Lapses of statutes of limitations	(4.2)

Balance at October 31, 2022	$	336.9

These tax benefits, if recognized, would reduce provision for income taxes for 2022, 2021 and 2020, by $324.3 million, $336.5 million, and $46.0 million, respectively. Interest and penalties related to unrecognized tax benefits are recognized in provision for income taxes. As of October 31, 2022, 2021 and 2020, accrued gross interest and penalties related to unrecognized tax benefits was $5.4 million, $6.4 million, and $7.3 million, respectively.

Included in the balance of unrecognized tax benefits at October 31, 2022 is $9.1 million related to tax positions for which it is reasonably possible that the total amounts could change during the next twelve months.

Filed tax returns are subject to examination by tax authorities in major tax jurisdictions after fiscal 2016, including the UK and the US.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Earnings Per Share

12 Months Ended

Oct. 31, 2022

Earnings Per Share [Abstract]

Earnings Per Share

Note 7. Earnings Per Share


Years Ended October 31,
(In millions, except for earnings per share)	2022		2021		2020
Net income	$	385.8	$	2,944.7	$	238.4
Basic:
Weighted average common shares	49.3		49.2		49.1
Basic earnings per share	$	7.83	$	59.80	$	4.85
Diluted:
Weighted average common shares	49.3		49.2		49.1
Effect of dilutive stock plans	0.4		0.6		0.5
Diluted weighted average common shares	49.7		49.8		49.6
Diluted earnings per share	$	7.76	$	59.16	$	4.81

The following table sets forth stock options to purchase our common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:


Years Ended October 31,
(In thousands, except exercise prices)	2022	2021		2020
Stock option shares excluded	227	107		207
Exercise prices	$300.12 - $406.17	$	345.74	$	304.54
Restricted stock units excluded	87	2		1

Stockholders' Equity

12 Months Ended

Oct. 31, 2022

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Note 8. Stockholders’ Equity

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):


(In millions)	Foreign Currency Translation Adjustment		Derivatives		Minimum Pension Liability		Total
Balance at October 31, 2019	$	(403.2)	$	—	$	(43.9)	$	(447.1)
Gross change in value	0.9		(17.1)		(16.8)		(33.0)
Tax effect	—		4.1		4.0		8.1

Balance at October 31, 2020	$	(402.3)	$	(13.0)	$	(56.7)	$	(472.0)
Gross change in value	$	82.2	$	34.3	$	29.8	$	146.3
Tax effect	(0.2)		(8.2)		(7.2)		(15.6)

Balance at October 31, 2021	$	(320.3)	$	13.1	$	(34.1)	$	(341.3)
Gross change in value	$	(234.7)	$	107.4	$	36.6	$	(90.7)

Tax effect	—		(26.1)		(8.7)		(34.8)
Balance at October 31, 2022	$	(555.0)	$	94.4	$	(6.2)	$	(466.8)

Share Repurchases

In December 2011, the Company's Board of Directors authorized the 2012 Share Repurchase Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company's common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements.

For the years ended October 31, 2022 and 2021, the Company's share repurchases were as follow:


Years Ended October 31,	2022		2021
Number of shares	191,165		69,622
Average repurchase price per share	$	410.4	$	356.6
Total costs of shares repurchased (in millions)	$	78.5	$	24.8

At October 31, 2022, $256.4 million remained authorized for repurchase under the program.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Stock Plans

12 Months Ended

Oct. 31, 2022

Share-Based Payment Arrangement [Abstract]

Stock Plans

Note 9. Stock Plans

2007 Long-Term Incentive Plan (2007 Plan)

In March 2007, we received stockholder approval of the 2007 Plan. The 2007 Plan was subsequently amended and restated, and granted stockholder approval in March 2009, March 2011, and March 2016.

The Third Amended and Restated 2007 Plan is designed to increase our stockholder value by attracting, retaining and motivating key employees and consultants who directly influence our profitability. The Third Amended and Restated 2007 Plan authorizes either our Board of Directors, or a designated committee thereof composed of two or more Non-Employee Directors, to grant to eligible individuals during the period ending December 31, 2026, up to 6,930,000 shares in the form of specified equity awards including stock options, restricted stock units and performance share awards, subject to adjustment for future stock splits, stock dividends, expirations, forfeitures and similar events. RSUs have no dividend or voting rights prior to vesting.

As of October 31, 2022, 690,596 shares remained available under the Third Amended and Restated 2007 Plan for future grants. The amount of available shares includes shares which may be distributed under performance share awards.

Share-Based Compensation

Compensation expense and the related tax benefit recognized in our Consolidated Statements of Income for share-based awards, including the Employee Stock Purchase Plan, were as follows:


October 31,
(In millions)	2022		2021		2020
Selling, general and administrative expense	$	46.7	$	38.4	$	32.2
Cost of sales	4.5		3.9		4.0
Research and development expense	3.0		2.4		2.4
Total compensation expense	$	54.2	$	44.7	$	38.6
Related income tax benefit	$	5.0	$	5.6	$	4.8

Stock Options

The fair value of each stock option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions noted in the following table.


Years Ended October 31,	2022		2021		2020
Expected life	4.1 years		4.0 years		4.4 years
Expected volatility	25.8	%	30.3	%	24.5	%
Risk-free interest rate	1.1	%	0.3	%	1.6	%
Dividend yield	0.02	%	0.02	%	0.02	%

The activity and status of our stock option plans are summarized below:


	Number of Shares	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at October 31, 2021	972,692	$	245.09
Granted	122,760	$	403.44
Exercised	(26,866)	$	171.87
Forfeited or expired	(4,743)	$	325.21
Outstanding at October 31, 2022	1,063,843	$	264.85	5.75
Vested and expected to vest at October 31, 2022	1,038,594	$	262.91	5.70	$	38,806,329
Vested and exercisable at October 31, 2022	624,512	$	223.45	4.57	$	35,586,767

The weighted-average fair value of options granted during fiscal 2022, 2021 and 2020, estimated as of the grant date using the Black-Scholes option pricing model, for the 2007 Plan was $90.41, $84.10 and $70.45, respectively. The total intrinsic value of options exercised during the fiscal years ended October 31, 2022, 2021 and 2020 was $6.6 million, $64.7 million and $22.6 million, respectively.

Stock options outstanding under our current plans have been granted at prices which are either equal to or above the market value of the common stock on the date of grant. Options granted under the 2007 Plan generally vest over a range of three to five years based on service conditions and expire no later than ten years after the grant date. Options granted under the 2020 Directors' Plan generally vest in one year and expire no later than ten years after the grant date. We generally recognize compensation expense ratably over the vesting period. As of October 31, 2022, there was $21.0 million of total unrecognized compensation cost related to nonvested options, which is expected to be recognized over a remaining weighted-average vesting period of 2.3 years.

Restricted Stock Units

RSUs granted under the 2007 Plan generally vest over three to five years. The grant-date fair value of RSUs is estimated based on the market price of our common stock. We recognize compensation expense ratably over the vesting period. As of October 31, 2022, there was $64.4 million of total unrecognized compensation cost related to nonvested RSUs, which is expected to be recognized over a remaining weighted-average vesting period of 2.5 years.

The status of our non-vested RSUs is summarized below:


	Number of Shares	Weighted- Average Grant Date Fair Value Per Share
Non-vested RSUs at October 31, 2021	317,335	$	293.80
Granted	113,079	$	399.21
Vested and issued	(113,301)	$	271.74
Forfeited or expired	(27,875)	$	324.67
Non-vested RSUs at October 31, 2022	289,238	$	340.68

Performance Units

Performance units may be granted to selected key employees with vesting contingent upon meeting future reported earnings per share goals over a defined performance cycle, usually three years. Performance units, if earned, may be paid in cash or shares of common stock. We granted performance unit awards on December 8, 2020 under the 2007 Plan. The performance shares actually earned will range from zero to 200% of the target number of performance shares for performance periods ending in fiscal 2021 through fiscal 2024. Subject to limited exceptions set forth in the performance share plan, any shares earned will be distributed in the subsequent fiscal year after the performance period. The fair value of performance unit awards is estimated on the date of grant based on the current market price of our common stock and the estimate of probability of award achievement. This estimate is reviewed each fiscal quarter and adjustments are recorded if it is determined that the estimate of probability of award achievement has changed.

We recognize compensation expense ratably over the vesting period. As of October 31, 2022, there was $11.2 million of total unrecognized compensation cost related to non-vested performance units, which is expected to be recognized over a remaining weighted-average vesting period of 1.8 years.

Employee Stock Purchase Plan

On March 18, 2019, the Company received stockholder approval for the Employee Stock Purchase Plan (ESPP). The first offering period began on November 4, 2019 and offerings are generally made on a quarterly basis. The purpose of the ESPP is to provide eligible employees of the Company with the opportunity to acquire shares of common stock at 85% of the market price on the last business day of each offering period by means of accumulated payroll deductions. The ESPP initially authorized the issuance of 1,000,000 shares of common stock. These shares will be made available from shares of common stock reacquired by the Company as Treasury Stock. During fiscal 2022 and 2021, we issued 22,695 and 17,575 shares to our employees under the ESPP, respectively. At October 31, 2022, the number of shares remaining available for future issuance under the ESPP was 948,090 shares. Total ESPP share-based compensation recognized during fiscal 2022 and 2021 was $1.1 million and $1.0 million, respectively.

Employee Benefits

12 Months Ended

Oct. 31, 2022

Retirement Benefits [Abstract]

Employee Benefits

Cooper's Retirement Income Plan

The Company's Retirement Income Plan (Plan), a defined benefit plan, is only available to full-time United States employees, subject to the soft freeze mentioned below. The Company's contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. The Company pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds.

The Company uses individual spot rates along the yield curve that correspond with the timing of each benefit payment to determine the service and interest costs of components of its net periodic benefit cost utilizing the correlation of projected cash outflows and corresponding spot rates on the yield curve.

The following table sets forth the Plan's benefit obligations and fair value of the Plan assets at October 31, 2022, 2021 and 2020 and the funded status of the Plan and net periodic pension costs for each of the years in the three-year periods ended October 31, 2022. The net amounts recognized in the Consolidated Balance Sheets consist of noncurrent liabilities. The accumulated benefit obligation was $134.9 million, $207.6 million and $195.8 million for the years ended October 31, 2022, 2021 and 2020.

Retirement Income Plan


Years Ended October 31, (In millions)	2022		2021		2020
Change in benefit obligation
Benefit obligation, beginning of year	$	230.9	$	218.8	$	189.7
Service cost	18.3		17.2		13.9
Interest cost	5.1		4.4		5.2
Benefits paid	(13.1)		(11.5)		(10.0)

Actuarial (gain)/loss	(93.2)		2.0		20.0
Benefit obligation, end of year	$	148.0	$	230.9	$	218.8
Change in plan assets
Fair value of plan assets, beginning of year	$	199.5	$	159.5	$	136.0
Actual return on plan assets	(43.5)		38.8		10.1
Employer contributions	—		12.7		23.4
Benefits paid	(13.1)		(11.5)		(10.0)
Fair value of plan assets, end of year	$	142.9	$	199.5	$	159.5
Funded status at end of year	$	(5.1)	$	(31.4)	$	(59.3)


Years Ended October 31, (In millions)	2022		2021		2020
Amounts recognized in accumulated other comprehensive income consist of:


Net loss	$	8.0	$	44.4	$	74.2
Accumulated other comprehensive income	$	8.0	$	44.4	$	74.2


Years Ended October 31, (In millions)	2022		2021		2020
Reconciliation of (prepaid) accrued pension cost:
(Prepaid)/Accrued pension cost at prior fiscal year end	$	(13.0)	$	(14.8)	$	(3.7)
Net periodic benefit cost	10.1		14.5		12.3
Contributions made during the year	—		(12.7)		(23.4)

(Prepaid)/Accrued pension cost at fiscal year end	$	(2.9)	$	(13.0)	$	(14.8)


Years Ended October 31, (In millions)	2022		2021		2020
Components of net periodic benefit cost and other amounts recognized in the Consolidated Statements of Income:
Net periodic benefit cost:
Service cost	$	18.3	$	17.2	$	13.9
Interest cost	5.1		4.4		5.2
Expected return on plan assets	(15.5)		(12.5)		(10.8)


Recognized actuarial loss	2.2		5.4		4.0
Net periodic pension cost	$	10.1	$	14.5	$	12.3


Years Ended October 31, (In millions)	2022		2021		2020
Other changes in plan assets and benefit obligations recognized in other comprehensive income:


Net (gain) loss	$	(34.1)	$	(24.4)	$	20.8


Amortizations of net gain	(2.5)		(5.4)		(4.0)



Total recognized in other comprehensive (income) loss	$	(36.6)	$	(29.8)	$	16.8
Total recognized in net periodic benefit cost and other comprehensive (income) loss	$	(26.2)	$	(15.2)	$	29.0


Years Ended October 31,	2022		2021		2020
Weighted-average assumptions used in computing the net periodic pension cost and projected benefit obligation at year end:
Discount rate for determining net periodic pension cost:
Projected Benefit Obligation	2.76	%	2.78	%	3.13	%
Service Cost	2.79	%	2.86	%	3.18	%
Interest Cost	2.28	%	2.07	%	2.78	%
Discount rate for determining benefit obligations at year end	5.74	%	2.76	%	2.78	%
Rate of compensation increase for determining expense	3.60	%	3.60	%	3.60	%
Rate of compensation increase for determining benefit obligations at year end	3.60	%	3.60	%	3.60	%
Expected rate of return on plan assets for determining net periodic pension cost	8.00	%	8.00	%	8.00	%
Expected rate of return on plan assets at year end	8.00	%	8.00	%	8.00	%
Measurement date for determining assets and benefit obligations at year end	10/31/2022		10/31/2021		10/31/2020

The discount rate enables us to state expected future cash flows at a present value on the measurement date. The discount rate used for the Plan is based primarily on the yields of a universe of high-quality corporate bonds rated AA or above, with durations corresponding to the expected durations of the benefit obligations. A change in the discount rate will cause the present value of benefit obligations to change in the opposite direction. If a discount rate of 2.76%, which is 0.02% lower than prior fiscal year, had been used, the projected benefit obligation would have been $217.2 million, and the accumulated benefit obligation would have been $194.2 million.

The expected rate of return on plan assets was determined based on a review of historical returns, both for this plan and for medium- to large-sized defined benefit pension funds with similar asset allocations. This review generated separate expected returns for each asset class listed below. These expected future returns were then blended based on this Plan's target asset allocation.

Reasons for Significant Liability Gains and Losses

The projected benefit obligation experienced a net gain of approximately $93.2 million during the year. This net gain is primarily due to gains from assumption changes of approximately $97.1 million, offset by losses of approximately $3.9 million

due to demographic experience. The key assumption changes were the increase in the discount rate (gain of $72.7 million), a change in the assumed payment form election probabilities (gain of $0.3 million), and changes in assumptions for lump sum determination (gain of $24.1 million). The primary reasons for demographic losses were the net effect of retirement rates, termination rates, salary increases and other experience that was different from assumed.

Plan Assets

Weighted-average asset allocations at year end, by asset category are as follows:


Years Ended October 31,	2022		2021		2020
Asset category
Cash and cash equivalents	2.0	%	5.0	%	11.8	%

Equity mutual funds	65.8	%	62.8	%	57.7	%
Hedging Strategy Funds	5.2	%	4.7	%	4.3	%

Bond mutual funds	27.0	%	27.5	%	26.2	%
Total	100.0	%	100.0	%	100.0	%

The Plan invests in a diversified portfolio of assets intended to minimize risk of poor returns while maximizing expected portfolio returns. To achieve the long-term rate of return, plan assets will be invested in a mixture of instruments, including but not limited to, corporate common stock (may include the Company's stock), investment grade bond funds, cash, balanced funds, real estate funds, small or large cap equity funds and international equity funds. The allocation of assets will be determined by the investment manager and will typically include 50% to 70% equities with the remainder invested in fixed income, hedging strategy funds and cash. Presently, this diversified portfolio is expected to return roughly 8% in the long run.

As of the measurement date of October 31, 2022, the fair value measurement of plan assets is as follows:


(In millions)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Asset category
Cash and cash equivalents	$	2.9	$	2.9	$	—	$	—

Equity mutual funds	93.9		93.9		—		—
Hedging Strategy Funds	7.5		7.5		—		—
Bond mutual funds	38.6		14.5		24.1		—
Total	$	142.9	$	118.8	$	24.1	$	—

The Plan has an established process for determining the fair value of plan assets. For investments in equity and bond mutual funds, and real estate funds, fair value is based on observable, Level 1 inputs.

While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Plan Cash Flows

Contributions

The Company made no contributions to the Plan in fiscal 2022. The Company contributions to the Plan were $12.7 million for fiscal 2021 and, $23.4 million for fiscal 2020. The Company closely monitors the funded status of the Plan with respect to legislative and accounting rules. The Company does not expect to make a contribution to the Plan during fiscal 2023.

Estimated Future Benefit Payments


Years (In millions)
2023	$	9.4
2024	$	11.0
2025	$	11.9
2026	$	11.4
2027	$	11.9
2028-2032	$	66.1

Plan Soft Freeze

On June 18, 2019 the Board of Directors of the Company approved a soft freeze of the Plan effective August 1, 2019. The Plan was closed to employees hired on or after August 1, 2019, including former participants or employees rehired on or after August 1, 2019 and employees hired in connection with a stock or asset acquisition, merger or other similar transaction on or after August 1, 2019. Existing employees already covered by the Plan, continue to accrue their benefits.

Cooper's 401(k) Savings Plan

Cooper's 401(k) savings plan provides for the deferral of compensation as described in the Internal Revenue Code and is available to substantially all United States employees. Employees who participate in the 401(k) plan may elect to have up to 75% of their pre-tax salary or wages deferred and contributed to the trust established under the Plan. Cooper's contributions on account of participating employees, were $9.0 million, $7.2 million and $6.8 million for the years ended October 31, 2022, 2021 and 2020, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Contingencies	12 Months Ended
Contingencies	Oct. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 11. Contingencies The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred.

Business Segment Information

12 Months Ended

Oct. 31, 2022

Segment Reporting [Abstract]

Business Segment Information

Note 12. Business Segment Information

The Company discloses information about its operating segments, which were established based on the way that management organizes segments within the Company for making operating decisions and assessing financial performance. The Company's two operating segments are described below.

•CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics.

•CooperSurgical. Competes in the general health care market with a focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women's health and fertility.

The Company uses operating income, as presented in our financial reports, as the primary measure of segment profitability. The Company does not allocate costs from corporate functions to segment operating income. The Company uses the same accounting policies to generate segment results as it does for consolidated results.

No customers accounted for 10% or more of our consolidated net revenue in fiscal 2022, 2021 and 2020.

Total identifiable assets are those used in continuing operations except cash and cash equivalents, which the Company includes as corporate assets.

The following table presents a summary of our business segment net sales:


(In millions)	2022		2021		2020
CooperVision net sales by category:
Toric lens	$	737.4	$	697.5	$	598.2
Multifocal lens	264.4		238.6		197.0
Single-use sphere lens	661.6		616.3		529.0
Non single-use sphere, other	579.9		599.6		518.8
Total CooperVision net sales	2,243.3		2,152.0		1,843.0
CooperSurgical net sales by category:
Office and surgical products	633.6		451.3		358.8
Fertility	431.5		319.2		229.1
Total CooperSurgical net sales	1,065.1		770.5		587.9
Total net sales	$	3,308.4	$	2,922.5	$	2,430.9

Information by business segment for each of the years in the three-year period ended October 31, 2022, follows:


(In millions)	CooperVision		CooperSurgical		Corporate		Consolidated
2022
Net sales	$	2,243.3	$	1,065.1	$	—	$	3,308.4
Operating income (loss)	$	494.3	$	67.1	$	(53.8)	$	507.6
Interest expense							57.3
Other (income), net							(25.0)
Income before income taxes							$	475.3
Identifiable assets	$	6,778.9	$	4,407.8	$	305.6	$	11,492.3
Depreciation expense	$	144.5	$	22.1	$	—	$	166.6
Amortization expense	$	32.3	$	147.2	$	—	$	179.5
Capital expenditures	$	223.0	$	19.0	$	—	$	242.0
2021
Net sales	$	2,152.0	$	770.5	$	—	$	2,922.5
Operating income (loss)	$	481.3	$	71.8	$	(47.3)	$	505.8
Interest expense							23.1
Other (income), net							(8.8)
Income before income taxes							$	491.5
Identifiable assets	$	6,965.9	$	2,395.6	$	244.7	$	9,606.2
Depreciation expense	$	148.3	$	14.9	$	—	$	163.2
Amortization expense	$	35.7	$	110.4	$	—	$	146.1
Capital expenditures	$	190.0	$	24.4	$	—	$	214.4
2020
Net sales	$	1,843.0	$	587.9	$	—	$	2,430.9
Operating income (loss)	$	375.7	$	(14.7)	$	(49.2)	$	311.8
Interest expense							36.8
Other expense, net							8.5
Income before income taxes							$	266.5
Identifiable assets	$	4,236.3	$	2,293.8	$	207.4	$	6,737.5
Depreciation expense	$	138.2	$	11.7	$	—	$	149.9
Amortization expense	$	32.4	$	104.8	$	—	$	137.2
Capital expenditures	$	260.3	$	50.1	$	—	$	310.4

Information by geographical area by country of domicile for each of the years in the three-year period ended October 31, 2022, follows:


(In millions)	United States		Europe		Rest of World, Other Eliminations & Corporate		Consolidated
2022
Net sales to unaffiliated customers	$	1,638.5	$	987.2	$	682.7	$	3,308.4
Sales between geographic areas	514.4		897.3		(1,411.7)		—
Net sales	$	2,152.9	$	1,884.5	$	(729.0)	$	3,308.4
Operating income	$	71.8	$	403.8	$	32.0	$	507.6
Long-lived assets	$	856.1	$	310.8	$	266.0	$	1,432.9
2021
Net sales to unaffiliated customers	$	1,339.2	$	957.9	$	625.4	$	2,922.5
Sales between geographic areas	494.9		815.1		(1,310.0)		—
Net sales	$	1,834.1	$	1,773.0	$	(684.6)	$	2,922.5
Operating (loss) income	$	(26.8)	$	416.2	$	116.4	$	505.8
Long-lived assets	$	737.5	$	377.2	$	232.9	$	1,347.6
2020
Net sales to unaffiliated customers	$	1,103.6	$	789.8	$	537.5	$	2,430.9
Sales between geographic areas	391.7		327.1		(718.8)		—
Net sales	$	1,495.3	$	1,116.9	$	(181.3)	$	2,430.9
Operating (loss) income	$	(14.5)	$	21.9	$	304.4	$	311.8
Long-lived assets	$	721.3	$	363.0	$	197.6	$	1,281.9

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Financial Derivatives and Hedging

12 Months Ended

Oct. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Derivatives and Hedging

Note 13. Financial Derivatives and Hedging

As part of the Company’s overall risk management practices the Company enters into financial derivatives, interest rate swaps designated as cash flow hedges, to hedge the Company's exposure to changes in cash flows associated with its variable rate debt.

Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk.

On April 6, 2020 the Company entered into six interest rate swap contracts which were used to hedge its exposure to changes in cash flows associated with its variable rate debt and were designated as derivatives in a cash flow hedge. The payment streams were based on a total notional amount of $1.5 billion at the inception of the contracts. As of October 31, 2022, three of the six interest rate swap contracts have matured and the outstanding contracts have a total notional amount of $1.0 billion and remaining maturities of five years or less..

The Company did not have any cross-currency swaps or foreign currency forward contracts as of October 31, 2022.

The pre-tax impact of gain on derivatives designated for hedge accounting recognized in other comprehensive income (loss) was $124.5 million ($30.1 million, net of tax) as of October 31, 2022. The pre-tax impact of gain on derivatives designated for hedge accounting recognized in other comprehensive income (loss) was $17.2 million ($13.1 million, net of tax) as of October 31, 2021. The fair value of derivative instruments are classified in "Other non-current assets" on our consolidated balance sheets.

The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Statements of Income:


Periods Ended October 31,
(In millions)		2022		2021		2020
Derivatives designated as cash flow hedges	Location of Loss (Income) Recognized on Derivatives
Interest rate swap contracts	Interest expense (income)	$	(2.3)	$	8.0	$	3.7

The Company expects that ($38.3 million) recorded as a component of accumulated other comprehensive income (loss) will be realized in the Consolidated Statements of Income over the next twelve months and the amount will vary depending on prevailing interest rates.

The following table details the changes in accumulated other comprehensive income:


(In millions)	Amount
Balance as of October 31, 2020	$	(17.1)
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($20.0, net of tax)	26.3
Amount reclassified from other comprehensive income into earnings, gross ($6.1, net of tax)	8
Balance gain as of October 31, 2021	$	17.2
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($79.7, net of tax)	105.1
Amount reclassified from other comprehensive income into earnings, gross ($1.7, net of tax)	2.2
Balance gain as of October 31, 2022	$	124.5

Schedule II

12 Months Ended

Oct. 31, 2022

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

VALUATION AND QUALIFYING ACCOUNTS

Three Years Ended October 31, 2022


(In millions)	Balance Beginning of Year	Additions	Reductions/ Charges	Balance at End of Year
Deferred income tax valuation allowance:
Year Ended October 31, 2022	51.8	13.3	(5.0)	60.1
Year Ended October 31, 2021	45.3	8.8	(2.3)	51.8
Year Ended October 31, 2020	41.5	5.9	(2.1)	45.3

Organization and Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidation	Principles of Consolidation The financial statements in this report include the results of all of Cooper's consolidated entities. All significant intercompany transactions and balances are eliminated on consolidation.
Use of Estimates	Use of Estimates The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates. In particular, the COVID-19 pandemic negatively impacted business and healthcare activity globally. As a result of healthcare systems responding to the demands of managing the pandemic, governments around the world imposing measures designed to reduce the transmission of the COVID-19 virus, and individuals responding to the concerns of contracting the COVID-19 virus, many optical practitioners and retailers, hospitals, medical offices and fertility clinics closed their facilities, restricted access, or delayed or canceled patient visits, exams and elective medical procedures, and many customers that have reopened are experiencing reduced patient visits. These factors have had, and in the future may have, an adverse effect on our sales, operating results and cash flows. The full extent to which the pandemic will directly or indirectly impact the Company's business, results of operations, and financial condition, including sales, expenses, manufacturing, clinical trials, research and development costs, reserves and allowances, fair value measurements, asset impairment charges, contingent consideration obligations, and the effectiveness of the Company's hedging instruments, will depend on future developments that are highly uncertain and difficult to predict. These developments include, but are not limited to, the duration and spread of the outbreak (including new and more contagious variants of COVID-19), its severity, the actions to contain the virus or address its impact, the timing, distribution, public acceptance and efficacy of vaccines and other treatments, United States and foreign government actions to respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume. There was not a material impact to the estimates in the Company’s Consolidated Financial Statements for fiscal 2022. The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material changes to the estimates and material impacts to the Company’s Consolidated Financial Statements in future reporting periods.
Revenue recognition	Revenue recognition Net Sales The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers may subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note 12. Business Segment Information for disaggregation of revenue. Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liabilities. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Trade Discounts and Allowances The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. Product Returns Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Historically, returns have been infrequent and insignificant relative to our total sales. Our refund liability for product returns was $14.5 million and $13.7 million at October 31, 2022 and 2021, respectively, which is included in Accrued Liabilities on our Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers. Rebates and Chargebacks Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served. Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical products in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis. Contract Liabilities Deferred revenue primarily represents prepaid stem cell storage as part of the CooperSurgical business unit. Revenue related to stem cell storage is recognized over the service period, which can range from one year to the lifetime of a customer.
Share-based Compensation	Share-Based Compensation We grant various share-based compensation awards, including stock options, performance unit shares, restricted stock and restricted stock units. The Company accounts for share-based compensation expense based on estimated grant-date fair value, and expenses the amount over the vesting period of the award. Determining the fair value of share-based awards at the grant date requires judgment, including estimating Cooper's stock price volatility, employee exercise behaviors and related employee forfeiture rates. The expected life of the share-based awards is based on the observed and expected time to post-vesting forfeiture and/or exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. In determining the expected volatility, management considers implied volatility from publicly-traded options on Cooper's common stock at the date of grant, historical volatility and other factors. The risk-free interest rate is based on the continuous rates provided by the United States Treasury with a term equal to the expected life of the award. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant. Forfeitures are estimated at the time of grant, based on historical experience, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Foreign Currency Translation	Foreign Currency Translation Most of our operations outside the United States use their local currency as their functional currency. We translate these assets and liabilities into United States dollars at year-end exchange rates. We translate income and expense accounts at average rates for each month. We record gains and losses from the translation of financial statements in foreign currencies into United States dollars in other comprehensive income. We record gains and losses from changes in exchange rates on transactions denominated in currencies other than each reporting location's functional currency in net income for each period.
Financial Derivatives and Hedging	Financial Derivatives and Hedging Derivatives are recorded on the Consolidation Balance Sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. The gain or loss on derivative instruments designated and qualifying for cash flow hedge accounting is deferred in other comprehensive income. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. Deferred gains or losses from designated cash flow hedges are reclassified into earnings in the period that the hedged interest expense affects earnings. The effectiveness of cash flow hedges is assessed at inception and quarterly thereafter. The Company does not offset fair value amounts recognized for derivative instruments in its Consolidated Balance Sheets for presentation purposes.
Fair Value Measurements	Fair Value Measurements Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. The carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms. The carrying value of the Company's revolving credit facility and term loans approximates fair value based on current market rates (Level 2). The fair value of the Company's interest rate swap contracts is measured on a recurring basis by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates (forward curves) derived from observable market interest rate curves. The interest rate swap contracts were categorized as Level 2 in the fair value hierarchy, as the inputs to the derivative pricing model are generally observable and do not contain a high level of subjectivity. The gain or loss on the derivatives is recorded as a component of accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Refer to Note 13. Financial Derivatives and Hedging for further information. The Company uses fair value measures when determining assets and liabilities acquired in an acquisition, which are considered a Level 3 measurement. The fair value of the Company's contingent consideration for which a liability is recorded and the initial measurement of the joint venture interest are a Level 3 measurement, and the change in fair value is recognized in selling, general and administrative expense in the Consolidated Statements of Income. Refer to Note 3. Acquisitions and Joint Venture for further information.
Income taxes	Income taxes Income taxes are estimated based on enacted income tax laws and the results of operations in each jurisdiction. Deferred tax assets and liabilities are estimated based on temporary differences between the financial reporting basis and income tax basis of assets and liabilities. Deferred tax assets are also estimated based on net operating loss and tax credit carryforwards. Deferred tax assets are reduced by a valuation allowance to the extent it is more likely than not they are not expected to be realized. Adjustments to deferred tax assets and liabilities due to changes in tax laws, changes in jurisdiction from intra-group transfers of assets, and changes in judgment regarding a valuation allowance are recognized in provision for income taxes in the quarter in which such changes occur. Long-term tax payable is estimated income tax to be paid for unrecognized tax benefits. A tax benefit is recognized if it is more likely than not a tax position will be sustained based on its technical merits in a tax authority examination, based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. Adjustments to unrecognized tax benefits due to changes in judgment are recognized in provision for income taxes in the quarter in which such changes occur. Interest and penalties related to unrecognized tax benefits are recognized in provision for income taxes.
Earnings Per Share	Earnings Per Share We determine basic earnings per share (EPS) by using the weighted average number of shares outstanding. We determine diluted EPS by increasing the weighted average number of shares outstanding in the denominator by the number of outstanding dilutive equity awards using the treasury stock method.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term, highly liquid investments purchased with maturities of three months or less to be cash equivalents.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis. In assessing the value of inventories, we make estimates and judgments regarding aging of inventories and other relevant issues potentially affecting the salable condition of products and estimated prices at which those products will sell. On an ongoing basis, we review the carrying value of our inventory, measuring number of months on hand and other indications of salability. We reduce the value of inventory if there are indications that the carrying value is greater than net realizable value, resulting in a new, lower-cost basis for that inventory. Subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. While estimates are involved, historically, obsolescence has not been a significant factor due to long product dating and lengthy product life cycles.
Property, Plant and Equipment	Property, Plant and Equipment We record property, plant, and equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally 3 to 15 years except for buildings which are depreciated over 30 to 40 years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.
Leases	Leases We consider an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. We have operating leases, but do not have material financing leases. The Company primarily has operating leases for office, manufacturing and warehouse space, vehicles, and office equipment. Lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the future minimum lease payments over the lease term. The lease term reflects the noncancellable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. Changes in the lease term assumption could impact the right-of-use assets and lease liabilities recognized on the Consolidated Balance Sheets. As our leases typically do not contain a readily determinable implicit rate, we determine the present value of the lease liability using our incremental borrowing rate at the lease commencement date based on the lease term on a collateralized basis. The Company’s operating leases typically include non-lease components such as common-area maintenance costs. The Company has elected to include non-lease components with lease payments for the purpose of calculating lease right-of-use assets and liabilities, to the extent that they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. Leases with a term of one year or less are not recognized on the Consolidated Balance Sheets, while the associated lease payments are expensed in the Consolidated Statements of Income and Comprehensive Income on a straight-line basis over the lease term. Operating leases are classified in “Other current liabilities”, “Accrued pension liability and other”, and “Other assets” on our consolidated balance sheets. Operating lease expense is recognized on a straight-line basis over the expected lease term and included in selling, general and administrative expenses in the Consolidated Statements of Income. Financing leases are classified in "Property, plant and equipment", "Short-term debt", and "Long-term debt" on our consolidated balance sheets.
Cloud Computing Arrangements	Cloud Computing Arrangements The Company capitalizes certain costs related to the acquisition and development of internal use software, including implementation costs incurred in a cloud computing arrangement, during the application development stages of projects. Capitalized implementation costs are amortized on a straight-line basis over the expected term of the hosting arrangement, which includes consideration of the non-cancellable contractual term and reasonably certain renewals. Costs incurred during the preliminary project or the post-implementation/operation stages of the project are expensed as incurred. Implementation costs are included in “Other assets” in the Consolidated Balance Sheets. Amortization of capitalized implementation costs is included in the same line item in the Consolidated Statements of Income as the expense for fees for the associated hosting arrangement.
Valuation of goodwill	Valuation of goodwill We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. Goodwill is tested for impairment at the reporting unit level by performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. We perform a qualitative assessment to test each reporting unit's goodwill for impairment, which includes industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value of the reporting unit.
Long-lived Assets	Long-lived Assets We review long-lived assets held and used, intangible assets with definite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset group are compared to the asset group's carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value. If management has committed to a plan to dispose of long-lived assets, the assets to be disposed of are reported at the lower of carrying amount or fair value less estimated costs to sell.
Indefinite-lived Intangible Assets	Indefinite-lived Intangible Assets We assess indefinite-lived intangible assets annually in the third quarter of the fiscal year, or whenever events or changes in circumstances indicate that the carrying amount of an indefinite-lived intangible asset (asset group) may not be recoverable. We evaluate whether the indefinite-lived intangible asset is impaired by comparing its carrying value to its fair value. If the carrying value of an indefinite-lived intangible asset is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value.
Business combinations	Business combinations We routinely consummate business combinations. Results of operations for acquired companies are included in our consolidated results of operations from the date of acquisition. We recognize separately from goodwill, the identifiable assets acquired, including acquired in-process research and development, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date fair values as defined by accounting standards related to fair value measurements. Key assumptions routinely utilized in allocation of purchase price to intangible assets include discount rates and projected financial information such as revenue projections for companies acquired. As of the acquisition date, goodwill is measured as the excess of consideration given, over the net of the acquisition date fair values of the identifiable assets acquired and the liabilities assumed. Direct acquisition costs are expensed as incurred.
Litigation	LitigationWe are subject to various legal proceedings, claims, litigation, investigations and contingencies arising out of the ordinary course of business. If we believe the likelihood of an adverse legal outcome is probable and the amount is estimable, we accrue a liability in accordance with accounting guidance for contingencies. We consult with legal counsel on matters related to litigation and seek input both within and outside the Company.
Treasury Stock	Treasury Stock We record treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.
Accounting Pronouncements Recently Adopted and Accounting Pronouncements Issued Not Yet Adopted	Accounting Pronouncements Recently Adopted On November 1, 2021, we prospectively adopted ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers to the business combinations entered into during fiscal 2022. This update requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. Accounting Pronouncements Issued Not Yet Adopted In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-04 on the Consolidated Condensed Financial Statements. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard is effective for fiscal years beginning after December 15, 2021, and should be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2021-10 on the Consolidated Condensed Financial Statements. No other recently issued accounting pronouncements had or are expected to have a material impact on our Consolidated Financial Statements.

Organization and Significant Accounting Policies (Tables)

12 Months Ended

Oct. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of inventory


October 31, (In millions)	2022		2021
Raw materials	$	173.7	$	137.7
Work-in-process	15.2		14.0
Finished goods	439.8		433.9
	$	628.7	$	585.6

Schedule of property, plant and equipment


October 31, (In millions)	2022		2021
Land and improvements	$	18.7	$	20.3
Buildings and improvements	415.6		388.0
Machinery and equipment	1,973.6		1,863.6
Construction in progress	393.0		383.8
Property, plant and equipment, at cost	$	2,800.9	$	2,655.7
Less: Accumulated depreciation	1,387.2		1,308.1
Property, plant and equipment, net	$	1,413.7	$	1,347.6
Finance lease ROU assets, net	19.2		—
	$	1,432.9	$	1,347.6

Operating Leases (Tables)

12 Months Ended

Oct. 31, 2022

Leases [Abstract]

Leases on the Consolidated Condensed Balance Sheet

The following table presents information about leases on the Consolidated Balance Sheets:


October 31, (In millions)	2022		2021
Operating Leases
Operating lease right-of-use assets	$	230.1	$	257.0

Operating lease liabilities, current	35.5		35.7
Operating lease liabilities, non-current	205.5		231.7
Total operating lease liabilities	$	241.0	$	267.4

Weighted average remaining lease term (in years)	9.8		10.6
Weighted average discount rate	3%		3%

Minimum rental payments required under operating leases

The minimum rental payments required under operating leases that have initial or remaining noncancellable lease terms in excess of one year as of October 31, 2022 are:


(In millions)
2023	$	42.2
2024	36.6
2025	32.8
2026	30.2
2027	26.6
Thereafter	115.8
Total lease payments	$	284.2
Less: interest	43.2
Present value of lease liabilities	$	241.0

Acquisitions and Joint Venture (Tables)

12 Months Ended

Oct. 31, 2022

Business Combination and Asset Acquisition [Abstract]

Total purchase consideration for business and asset acquisitions

The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2022, 2021, and 2020:


(In millions)	2022		2021		2020
Technology	$	1.9	$	178.6	$	—
In-Process Research & Development (IPR&D)	—		20.0		—
Customer relationships	729.2		7.5		11.4
Trademarks	55.4		1.3		5.1
Other	—		0.6		3.9
Total identifiable intangible assets	$	786.5	$	208.0	$	20.4

Goodwill	1,184.8		91.6		15.3
Net tangible liabilities	(286.5)		(10.8)		(0.3)
Fair value of contingent consideration	(1.5)		(39.1)		—
Total closing purchase price	$	1,683.3	$	249.7	$	35.4

Schedule of recognized identified assets acquired and liabilities assumed

The following table summarizes the preliminary fair values of assets acquired and liabilities assumed as of the acquisition date:


(In millions)
Current assets:
Cash and cash equivalents	$	58.6
Trade accounts receivable, net	18.1
Inventories	3.3
Prepaid expense and other current assets	33.5
Total current assets	113.5
Property, plant and equipment	42.6

Goodwill	1,177.3
Customer relationships	718.3
Trademarks	54.9

Other assets	21.5
Total assets acquired	$	2,128.1

Current liabilities:
Accounts payable	$	12.6
Employee compensation and benefits	12.3

Deferred revenue	68.0
Other current liabilities	12.4
Total current liabilities	105.3
Deferred tax liabilities	147.3

Lease liabilities	16.6
Deferred revenue	192.2

Other long-term liabilities	3.6
Total liabilities assumed	$	465.0

Total purchase price	$	1,663.1

Contingent consideration reconciliation

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:


(In millions)	2022		2021
Beginning balance	$	97.4	$	—
Purchase price contingent consideration	1.5		31.3
Payments	(55.2)		—
Change in fair value	(10.3)		66.1
Ending balance	$	33.4	$	97.4

Schedule of business acquisition, pro forma information

The following unaudited pro forma information summarizes the combined results of operations of the Company and Generate as if the acquisition had been completed at the beginning of the Company’s fiscal 2021:


(In millions)	2022		2021
Revenue	$	3,344.3	$	3,183.2
Net income	$	370.7	$	2,959.8

Intangible Assets (Tables)

12 Months Ended

Oct. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of goodwill


(In millions)	CooperVision		CooperSurgical		Total




Balance at October 31, 2021	$	1,841.0	$	733.0	$	2,574.0
Net additions	0.9		1,183.9		1,184.8

Foreign currency translation adjustment	(131.6)		(17.5)		(149.1)
Balance at October 31, 2022	$	1,710.3	$	1,899.4	$	3,609.7

Schedule of finite-lived intangible assets

Other Intangible Assets


	October 31, 2022				October 31, 2021
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted Average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	209.6	$	62.4	$	156.7	$	49.1	15
Composite intangible asset	1,061.9		354.0		1,061.8		283.2		15
Technology	504.1		317.5		513.0		287.9		12
Customer relationships	1,092.7		287.0		378.4		240.1		19
License and distribution rights and other	50.7		23.8		33.4		21.6		11
	2,919.0		$	1,044.7	2,143.3		$	881.9	16
Less: accumulated amortization and translation	1,044.7				881.9
Intangible assets with definite lives, net	$	1,874.3			$	1,261.4
Intangible assets with indefinite lives, net (1)	10.8				10.1
Total other intangibles, net	$	1,885.1			$	1,271.5

(1) Intangible assets with indefinite lives include technology and trademarks.

Schedule of indefinite-lived intangible assets

Other Intangible Assets


	October 31, 2022				October 31, 2021
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted Average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	209.6	$	62.4	$	156.7	$	49.1	15
Composite intangible asset	1,061.9		354.0		1,061.8		283.2		15
Technology	504.1		317.5		513.0		287.9		12
Customer relationships	1,092.7		287.0		378.4		240.1		19
License and distribution rights and other	50.7		23.8		33.4		21.6		11
	2,919.0		$	1,044.7	2,143.3		$	881.9	16
Less: accumulated amortization and translation	1,044.7				881.9
Intangible assets with definite lives, net	$	1,874.3			$	1,261.4
Intangible assets with indefinite lives, net (1)	10.8				10.1
Total other intangibles, net	$	1,885.1			$	1,271.5

(1) Intangible assets with indefinite lives include technology and trademarks.

Remaining amortization expenses for intangible assets with definite lives

As of October 31, 2022, the estimate of future amortization expenses for intangible assets with definite lives is as follows:


Fiscal years:	(In millions)
2023	$	183.2
2024	179.2
2025	169.3
2026	162.0
Thereafter	1,180.6
Total remaining amortization for intangible assets with definite lives	$	1,874.3

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Debt (Tables)

12 Months Ended

Oct. 31, 2022

Debt Disclosure [Abstract]

Schedule of debt

The Company had outstanding debt as follows:


October 31, (In millions)	2022		2021


Overdraft and other credit facilities	$	57.7	$	83.0
Term loans	338.0		—
Less: unamortized debt issuance cost	—		(0.1)
Short-term debt, excluding financing leases	395.7		82.9
Financing lease liabilities	16.9		0.5
Short-term debt	$	412.6	$	83.4

Revolving credit	$	—	$	546.1
Term loans	2,350.0		850.0
Other	0.2		0.2
Less: unamortized debt issuance cost	(3.1)		(0.2)
Long-term debt, excluding financing leases	2,347.1		1,396.1

Financing lease liabilities	3.7		1.5
Long-term debt	$	2,350.8	$	1,397.6
Total debt	$	2,763.4	$	1,481.0

Income Taxes (Tables)

12 Months Ended

Oct. 31, 2022

Income Tax Disclosure [Abstract]

Income before income taxes

Components of income before income taxes:


Years Ended October 31, (In millions)	2022		2021		2020
Income before income taxes:
United States	$	31.4	$	(31.0)	$	(88.0)
Foreign	443.9		522.5		354.5
	$	475.3	$	491.5	$	266.5

Provision for income taxes

Components of provision for income taxes:


Years Ended October 31, (In millions)	2022		2021		2020
Current:
Federal	$	10.2	$	21.0	$	1.4
State	3.8		1.3		1.1
Foreign	21.7		26.7		26.5
	35.7		49.0		29.0

Deferred:
Federal	10.5		(8.8)		3.2
State	(2.2)		(0.5)		0.8
Foreign	45.6		(2,492.9)		(4.9)
	53.9		(2,502.2)		(0.9)
Provision for income taxes	$	89.5	$	(2,453.2)	$	28.1

Reconciliation between the expected provision for income taxes at the US federal statutory rate and the provision for income taxes

Reconciliation between the expected provision for income taxes at the US federal statutory rate and the provision for income taxes:


Years Ended October 31, (In millions)	2022		2021		2020
Provision for income taxes at United States statutory tax rate	$	99.8	$	103.2	$	56.0
(Decrease) increase in taxes resulting from:
Foreign earnings in jurisdictions with lower tax rates	(22.3)		(43.6)		(54.7)
Foreign earnings subject to United States tax	20.7		25.4		32.0

Excess tax benefits from share-based compensation	(2.6)		(13.0)		(6.2)
Deferred tax asset step-up	(3.4)		3.2		(9.0)
United States provision-to-return	0.5		(1.2)		7.0
Intra-group transfer to UK subsidiary	—		(1,987.8)		—
Remeasurement of deferred tax assets from UK rate change	—		(536.7)		—
Change in unrecognized tax benefits	(12.7)		(7.6)		(0.1)
State tax provision	5.0		0.8		1.9
Other, net	4.5		4.1		1.2
Provision for income taxes	$	89.5	$	(2,453.2)	$	28.1

Deferred tax assets and liabilities

Components of deferred tax assets and liabilities:


Years Ended October 31, (In millions)	2022		2021
Deferred tax assets:
Accounts receivable	$	4.9	$	3.4
Inventories	6.3		6.1
Accrued liabilities, reserves and compensation accruals	79.9		78.1
Foreign deferred tax assets	2,500.5		2,531.5
Share-based compensation	14.5		28.6
Net operating loss and tax credit carryforwards	19.6		19.3
Intangible assets	—		6.8
Capitalized research and experimental expenses	15.4		13.5
Total gross deferred tax assets	2,641.1		2,687.3
Less: valuation allowance	(60.1)		(51.8)
Deferred tax assets	2,581.0		2,635.5
Deferred tax liabilities:
Tax deductible goodwill	(39.7)		(34.0)
Intangible assets	(153.8)		—
Plant and equipment	(48.8)		(46.5)
Foreign deferred tax liabilities	(45.5)		(32.5)


Total gross deferred tax liabilities	(287.8)		(113.0)
Net deferred tax assets	$	2,293.2	$	2,522.5

Changes in unrecognized tax benefits

Changes in unrecognized tax benefits:


(In millions)
Balance at October 31, 2020	$	58.5
Decrease based on tax positions in prior fiscal years	(8.3)
Increase based on tax positions in current fiscal year	307.2
Settlements	(1.9)
Lapses of statutes of limitations	(1.7)
Balance at October 31, 2021	$	353.8
Decrease based on tax positions in prior fiscal years	(12.5)

Settlements	(0.2)

Lapses of statutes of limitations	(4.2)

Balance at October 31, 2022	$	336.9

Earnings Per Share (Tables)

12 Months Ended

Oct. 31, 2022

Earnings Per Share [Abstract]

Schedule of earnings per share


Years Ended October 31,
(In millions, except for earnings per share)	2022		2021		2020
Net income	$	385.8	$	2,944.7	$	238.4
Basic:
Weighted average common shares	49.3		49.2		49.1
Basic earnings per share	$	7.83	$	59.80	$	4.85
Diluted:
Weighted average common shares	49.3		49.2		49.1
Effect of dilutive stock plans	0.4		0.6		0.5
Diluted weighted average common shares	49.7		49.8		49.6
Diluted earnings per share	$	7.76	$	59.16	$	4.81

Stock options to purchase common stock and restricted stock units not included in diluted earnings per share calculation due to antidilutive effect


Years Ended October 31,
(In thousands, except exercise prices)	2022	2021		2020
Stock option shares excluded	227	107		207
Exercise prices	$300.12 - $406.17	$	345.74	$	304.54
Restricted stock units excluded	87	2		1

Stockholders' Equity (Tables)

12 Months Ended

Oct. 31, 2022

Stockholders' Equity Note [Abstract]

Changes in accumulated other comprehensive (loss) income

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):


(In millions)	Foreign Currency Translation Adjustment		Derivatives		Minimum Pension Liability		Total
Balance at October 31, 2019	$	(403.2)	$	—	$	(43.9)	$	(447.1)
Gross change in value	0.9		(17.1)		(16.8)		(33.0)
Tax effect	—		4.1		4.0		8.1

Balance at October 31, 2020	$	(402.3)	$	(13.0)	$	(56.7)	$	(472.0)
Gross change in value	$	82.2	$	34.3	$	29.8	$	146.3
Tax effect	(0.2)		(8.2)		(7.2)		(15.6)

Balance at October 31, 2021	$	(320.3)	$	13.1	$	(34.1)	$	(341.3)
Gross change in value	$	(234.7)	$	107.4	$	36.6	$	(90.7)

Tax effect	—		(26.1)		(8.7)		(34.8)
Balance at October 31, 2022	$	(555.0)	$	94.4	$	(6.2)	$	(466.8)

The following table details the changes in accumulated other comprehensive income:


(In millions)	Amount
Balance as of October 31, 2020	$	(17.1)
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($20.0, net of tax)	26.3
Amount reclassified from other comprehensive income into earnings, gross ($6.1, net of tax)	8
Balance gain as of October 31, 2021	$	17.2
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($79.7, net of tax)	105.1
Amount reclassified from other comprehensive income into earnings, gross ($1.7, net of tax)	2.2
Balance gain as of October 31, 2022	$	124.5

Schedule of share repurchases

For the years ended October 31, 2022 and 2021, the Company's share repurchases were as follow:


Years Ended October 31,	2022		2021
Number of shares	191,165		69,622
Average repurchase price per share	$	410.4	$	356.6
Total costs of shares repurchased (in millions)	$	78.5	$	24.8

Stock Plans (Tables)

12 Months Ended

Oct. 31, 2022

Share-Based Payment Arrangement [Abstract]

Compensation expense and related income tax benefit for share-based awards

Compensation expense and the related tax benefit recognized in our Consolidated Statements of Income for share-based awards, including the Employee Stock Purchase Plan, were as follows:


October 31,
(In millions)	2022		2021		2020
Selling, general and administrative expense	$	46.7	$	38.4	$	32.2
Cost of sales	4.5		3.9		4.0
Research and development expense	3.0		2.4		2.4
Total compensation expense	$	54.2	$	44.7	$	38.6
Related income tax benefit	$	5.0	$	5.6	$	4.8

Assumptions used in estimating fair value of stock options award granted


Years Ended October 31,	2022		2021		2020
Expected life	4.1 years		4.0 years		4.4 years
Expected volatility	25.8	%	30.3	%	24.5	%
Risk-free interest rate	1.1	%	0.3	%	1.6	%
Dividend yield	0.02	%	0.02	%	0.02	%

Schedule of stock option plans

The activity and status of our stock option plans are summarized below:


	Number of Shares	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at October 31, 2021	972,692	$	245.09
Granted	122,760	$	403.44
Exercised	(26,866)	$	171.87
Forfeited or expired	(4,743)	$	325.21
Outstanding at October 31, 2022	1,063,843	$	264.85	5.75
Vested and expected to vest at October 31, 2022	1,038,594	$	262.91	5.70	$	38,806,329
Vested and exercisable at October 31, 2022	624,512	$	223.45	4.57	$	35,586,767

Schedule of non-vested RSUs

The status of our non-vested RSUs is summarized below:


	Number of Shares	Weighted- Average Grant Date Fair Value Per Share
Non-vested RSUs at October 31, 2021	317,335	$	293.80
Granted	113,079	$	399.21
Vested and issued	(113,301)	$	271.74
Forfeited or expired	(27,875)	$	324.67
Non-vested RSUs at October 31, 2022	289,238	$	340.68

Employee Benefits (Tables)

12 Months Ended

Oct. 31, 2022

Retirement Benefits [Abstract]

Changes in benefit obligation, changes in plan assets and funded status

Retirement Income Plan


Years Ended October 31, (In millions)	2022		2021		2020
Change in benefit obligation
Benefit obligation, beginning of year	$	230.9	$	218.8	$	189.7
Service cost	18.3		17.2		13.9
Interest cost	5.1		4.4		5.2
Benefits paid	(13.1)		(11.5)		(10.0)

Actuarial (gain)/loss	(93.2)		2.0		20.0
Benefit obligation, end of year	$	148.0	$	230.9	$	218.8
Change in plan assets
Fair value of plan assets, beginning of year	$	199.5	$	159.5	$	136.0
Actual return on plan assets	(43.5)		38.8		10.1
Employer contributions	—		12.7		23.4
Benefits paid	(13.1)		(11.5)		(10.0)
Fair value of plan assets, end of year	$	142.9	$	199.5	$	159.5
Funded status at end of year	$	(5.1)	$	(31.4)	$	(59.3)

Amounts recognized in accumulated other comprehensive Income


Years Ended October 31, (In millions)	2022		2021		2020
Amounts recognized in accumulated other comprehensive income consist of:


Net loss	$	8.0	$	44.4	$	74.2
Accumulated other comprehensive income	$	8.0	$	44.4	$	74.2

Reconciliation of prepaid (accrued) pension cost


Years Ended October 31, (In millions)	2022		2021		2020
Reconciliation of (prepaid) accrued pension cost:
(Prepaid)/Accrued pension cost at prior fiscal year end	$	(13.0)	$	(14.8)	$	(3.7)
Net periodic benefit cost	10.1		14.5		12.3
Contributions made during the year	—		(12.7)		(23.4)

(Prepaid)/Accrued pension cost at fiscal year end	$	(2.9)	$	(13.0)	$	(14.8)

Components of net periodic pension costs and other amounts recognized in other comprehensive income


Years Ended October 31, (In millions)	2022		2021		2020
Components of net periodic benefit cost and other amounts recognized in the Consolidated Statements of Income:
Net periodic benefit cost:
Service cost	$	18.3	$	17.2	$	13.9
Interest cost	5.1		4.4		5.2
Expected return on plan assets	(15.5)		(12.5)		(10.8)


Recognized actuarial loss	2.2		5.4		4.0
Net periodic pension cost	$	10.1	$	14.5	$	12.3

Other changes in plan assets and benefit obligations recognized in other comprehensive income


Years Ended October 31, (In millions)	2022		2021		2020
Other changes in plan assets and benefit obligations recognized in other comprehensive income:


Net (gain) loss	$	(34.1)	$	(24.4)	$	20.8


Amortizations of net gain	(2.5)		(5.4)		(4.0)



Total recognized in other comprehensive (income) loss	$	(36.6)	$	(29.8)	$	16.8
Total recognized in net periodic benefit cost and other comprehensive (income) loss	$	(26.2)	$	(15.2)	$	29.0

Weighted-average assumptions used in computing net periodic pension cost and projected benefit obligation


Years Ended October 31,	2022		2021		2020
Weighted-average assumptions used in computing the net periodic pension cost and projected benefit obligation at year end:
Discount rate for determining net periodic pension cost:
Projected Benefit Obligation	2.76	%	2.78	%	3.13	%
Service Cost	2.79	%	2.86	%	3.18	%
Interest Cost	2.28	%	2.07	%	2.78	%
Discount rate for determining benefit obligations at year end	5.74	%	2.76	%	2.78	%
Rate of compensation increase for determining expense	3.60	%	3.60	%	3.60	%
Rate of compensation increase for determining benefit obligations at year end	3.60	%	3.60	%	3.60	%
Expected rate of return on plan assets for determining net periodic pension cost	8.00	%	8.00	%	8.00	%
Expected rate of return on plan assets at year end	8.00	%	8.00	%	8.00	%
Measurement date for determining assets and benefit obligations at year end	10/31/2022		10/31/2021		10/31/2020

Weighted-average asset allocations and fair value measurement of plan assets

Plan Assets

Weighted-average asset allocations at year end, by asset category are as follows:


Years Ended October 31,	2022		2021		2020
Asset category
Cash and cash equivalents	2.0	%	5.0	%	11.8	%

Equity mutual funds	65.8	%	62.8	%	57.7	%
Hedging Strategy Funds	5.2	%	4.7	%	4.3	%

Bond mutual funds	27.0	%	27.5	%	26.2	%
Total	100.0	%	100.0	%	100.0	%

As of the measurement date of October 31, 2022, the fair value measurement of plan assets is as follows:


(In millions)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Asset category
Cash and cash equivalents	$	2.9	$	2.9	$	—	$	—

Equity mutual funds	93.9		93.9		—		—
Hedging Strategy Funds	7.5		7.5		—		—
Bond mutual funds	38.6		14.5		24.1		—
Total	$	142.9	$	118.8	$	24.1	$	—

Estimated future benefit payments

Estimated Future Benefit Payments


Years (In millions)
2023	$	9.4
2024	$	11.0
2025	$	11.9
2026	$	11.4
2027	$	11.9
2028-2032	$	66.1

Business Segment Information (Tables)

12 Months Ended

Oct. 31, 2022

Segment Reporting [Abstract]

Schedule of business segment net sales

The following table presents a summary of our business segment net sales:


(In millions)	2022		2021		2020
CooperVision net sales by category:
Toric lens	$	737.4	$	697.5	$	598.2
Multifocal lens	264.4		238.6		197.0
Single-use sphere lens	661.6		616.3		529.0
Non single-use sphere, other	579.9		599.6		518.8
Total CooperVision net sales	2,243.3		2,152.0		1,843.0
CooperSurgical net sales by category:
Office and surgical products	633.6		451.3		358.8
Fertility	431.5		319.2		229.1
Total CooperSurgical net sales	1,065.1		770.5		587.9
Total net sales	$	3,308.4	$	2,922.5	$	2,430.9

Schedule of business segment information

Information by business segment for each of the years in the three-year period ended October 31, 2022, follows:


(In millions)	CooperVision		CooperSurgical		Corporate		Consolidated
2022
Net sales	$	2,243.3	$	1,065.1	$	—	$	3,308.4
Operating income (loss)	$	494.3	$	67.1	$	(53.8)	$	507.6
Interest expense							57.3
Other (income), net							(25.0)
Income before income taxes							$	475.3
Identifiable assets	$	6,778.9	$	4,407.8	$	305.6	$	11,492.3
Depreciation expense	$	144.5	$	22.1	$	—	$	166.6
Amortization expense	$	32.3	$	147.2	$	—	$	179.5
Capital expenditures	$	223.0	$	19.0	$	—	$	242.0
2021
Net sales	$	2,152.0	$	770.5	$	—	$	2,922.5
Operating income (loss)	$	481.3	$	71.8	$	(47.3)	$	505.8
Interest expense							23.1
Other (income), net							(8.8)
Income before income taxes							$	491.5
Identifiable assets	$	6,965.9	$	2,395.6	$	244.7	$	9,606.2
Depreciation expense	$	148.3	$	14.9	$	—	$	163.2
Amortization expense	$	35.7	$	110.4	$	—	$	146.1
Capital expenditures	$	190.0	$	24.4	$	—	$	214.4
2020
Net sales	$	1,843.0	$	587.9	$	—	$	2,430.9
Operating income (loss)	$	375.7	$	(14.7)	$	(49.2)	$	311.8
Interest expense							36.8
Other expense, net							8.5
Income before income taxes							$	266.5
Identifiable assets	$	4,236.3	$	2,293.8	$	207.4	$	6,737.5
Depreciation expense	$	138.2	$	11.7	$	—	$	149.9
Amortization expense	$	32.4	$	104.8	$	—	$	137.2
Capital expenditures	$	260.3	$	50.1	$	—	$	310.4

Schedule of information by geographical area by country of domicile

Information by geographical area by country of domicile for each of the years in the three-year period ended October 31, 2022, follows:


(In millions)	United States		Europe		Rest of World, Other Eliminations & Corporate		Consolidated
2022
Net sales to unaffiliated customers	$	1,638.5	$	987.2	$	682.7	$	3,308.4
Sales between geographic areas	514.4		897.3		(1,411.7)		—
Net sales	$	2,152.9	$	1,884.5	$	(729.0)	$	3,308.4
Operating income	$	71.8	$	403.8	$	32.0	$	507.6
Long-lived assets	$	856.1	$	310.8	$	266.0	$	1,432.9
2021
Net sales to unaffiliated customers	$	1,339.2	$	957.9	$	625.4	$	2,922.5
Sales between geographic areas	494.9		815.1		(1,310.0)		—
Net sales	$	1,834.1	$	1,773.0	$	(684.6)	$	2,922.5
Operating (loss) income	$	(26.8)	$	416.2	$	116.4	$	505.8
Long-lived assets	$	737.5	$	377.2	$	232.9	$	1,347.6
2020
Net sales to unaffiliated customers	$	1,103.6	$	789.8	$	537.5	$	2,430.9
Sales between geographic areas	391.7		327.1		(718.8)		—
Net sales	$	1,495.3	$	1,116.9	$	(181.3)	$	2,430.9
Operating (loss) income	$	(14.5)	$	21.9	$	304.4	$	311.8
Long-lived assets	$	721.3	$	363.0	$	197.6	$	1,281.9

Financial Derivatives and Hedging (Tables)

12 Months Ended

Oct. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative instruments recognized in condensed consolidated statements of income

The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Statements of Income:


Periods Ended October 31,
(In millions)		2022		2021		2020
Derivatives designated as cash flow hedges	Location of Loss (Income) Recognized on Derivatives
Interest rate swap contracts	Interest expense (income)	$	(2.3)	$	8.0	$	3.7

Changes in accumulated other comprehensive (loss) income

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):


(In millions)	Foreign Currency Translation Adjustment		Derivatives		Minimum Pension Liability		Total
Balance at October 31, 2019	$	(403.2)	$	—	$	(43.9)	$	(447.1)
Gross change in value	0.9		(17.1)		(16.8)		(33.0)
Tax effect	—		4.1		4.0		8.1

Balance at October 31, 2020	$	(402.3)	$	(13.0)	$	(56.7)	$	(472.0)
Gross change in value	$	82.2	$	34.3	$	29.8	$	146.3
Tax effect	(0.2)		(8.2)		(7.2)		(15.6)

Balance at October 31, 2021	$	(320.3)	$	13.1	$	(34.1)	$	(341.3)
Gross change in value	$	(234.7)	$	107.4	$	36.6	$	(90.7)

Tax effect	—		(26.1)		(8.7)		(34.8)
Balance at October 31, 2022	$	(555.0)	$	94.4	$	(6.2)	$	(466.8)

The following table details the changes in accumulated other comprehensive income:


(In millions)	Amount
Balance as of October 31, 2020	$	(17.1)
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($20.0, net of tax)	26.3
Amount reclassified from other comprehensive income into earnings, gross ($6.1, net of tax)	8
Balance gain as of October 31, 2021	$	17.2
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($79.7, net of tax)	105.1
Amount reclassified from other comprehensive income into earnings, gross ($1.7, net of tax)	2.2
Balance gain as of October 31, 2022	$	124.5

Organization and Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended	12 Months Ended
	Oct. 31, 2022 USD ($)	Oct. 31, 2022 USD ($) business_unit	Oct. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)
Property, Plant and Equipment [Line Items]
Number of business units \| business_unit		2
Refund liability for product returns	$ 14.5	$ 14.5	$ 13.7
Net foreign exchange loss		22.0	$ 5.5	$ 1.2
Exit charges	$ 9.2	33.2
Cost of sales
Property, Plant and Equipment [Line Items]
Exit charges		26.7
Selling, general and administrative expense
Property, Plant and Equipment [Line Items]
Exit charges		$ 6.5
Minimum
Property, Plant and Equipment [Line Items]
Capitalized contract cost, amortization period (or less)	1 year	1 year
Property, plant and equipment, useful life		3 years
Total exit costs expected	$ 30.0	$ 30.0
Minimum \| Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		30 years
Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		15 years
Total exit costs expected	$ 40.0	$ 40.0
Maximum \| Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		40 years

Organization and Significant Accounting Policies - Inventory (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 173.7	$ 137.7
Work-in-process	15.2	14.0
Finished goods	439.8	433.9
Inventories, net	$ 628.7	$ 585.6

Organization and Significant Accounting Policies - Property Plant and Equipment (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 2,800.9	$ 2,655.7
Less: Accumulated depreciation	1,387.2	1,308.1
Property, plant and equipment, net	1,413.7	1,347.6
Finance lease ROU assets, net	19.2	0.0
Property, plant and equipment, net	1,432.9	1,347.6	$ 1,281.9
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	18.7	20.3
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	415.6	388.0
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	1,973.6	1,863.6
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 393.0	$ 383.8

Operating Leases - Leases on the Consolidated Condensed Balance Sheet (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Operating Leases
Operating lease right-of-use assets	$ 230.1	$ 257.0
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Operating lease liabilities, current	$ 35.5	$ 35.7
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Operating lease liabilities, non-current	$ 205.5	$ 231.7
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Accrued pension liability and other	Accrued pension liability and other
Total operating lease liabilities	$ 241.0	$ 267.4
Weighted average remaining lease term (in years)	9 years 9 months 18 days	10 years 7 months 6 days
Weighted average discount rate	3.00%	3.00%

Operating Leases - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Leases [Abstract]
Operating lease expense	$ 45.0	$ 44.1	$ 41.2

Operating Leases - Minimum Rental Payments Required Under Operating Leases (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Leases [Abstract]
2023	$ 42.2
2024	36.6
2025	32.8
2026	30.2
2027	26.6
Thereafter	115.8
Total lease payments	284.2
Less: interest	43.2
Present value of lease liabilities	$ 241.0	$ 267.4

Acquisitions and Joint Venture - Total Purchase Consideration for Business and Asset Acquisitions (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Goodwill	$ 3,609.7	$ 2,574.0
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	786.5	208.0	$ 20.4
Goodwill	1,184.8	91.6	15.3
Net tangible liabilities	(286.5)	(10.8)	(0.3)
Fair value of contingent consideration	(1.5)	(39.1)	0.0
Total closing purchase price	1,683.3	249.7	35.4
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| Technology
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	1.9	178.6	0.0
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| In-Process Research & Development (IPR&D)
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	0.0	20.0	0.0
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| Customer relationships
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	729.2	7.5	11.4
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| Trademarks
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	55.4	1.3	5.1
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| Other
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	$ 0.0	$ 0.6	$ 3.9

Acquisitions and Joint Venture - Narrative (Details) - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 17, 2021	Mar. 31, 2022	Jan. 31, 2023	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020	Feb. 01, 2021	Jan. 19, 2021
Business Acquisition [Line Items]
Useful life				16 years
Goodwill				$ 3,609,700,000	$ 2,574,000,000
Proceeds from sale of interest in a subsidiary		$ 52,100,000		$ 52,100,000	$ 0	$ 0
Payments to form joint venture		10,000,000
Equity method investments		90,000,000
Equity method investment realized gain		56,900,000
Privately-Held Medical Device Company, Developed Mara Water Vapor Ablation System
Business Acquisition [Line Items]
Goodwill							$ 0
Essilor International SAS
Business Acquisition [Line Items]
Payments to form joint venture		$ 10,000,000
SightGlass Vision, Inc.
Business Acquisition [Line Items]
Equity method investment, ownership percentage		50.00%
Customer relationships
Business Acquisition [Line Items]
Useful life				19 years
Trademarks
Business Acquisition [Line Items]
Useful life				15 years
Line of Credit \| Term Loan Facility 2021
Business Acquisition [Line Items]
Proceeds from line of credit	$ 1,500,000,000
Cook Medicals Reproductive Health Business \| Forecast \| Subsequent Event
Business Acquisition [Line Items]
Purchase price to acquire business			$ 875,000,000
Payments to acquire business			675,000,000
Payables incurred in acquisition			200,000,000
Cook Medicals Reproductive Health Business \| Forecast \| Subsequent Event \| Payables First Installment
Business Acquisition [Line Items]
Payables incurred in acquisition			50,000,000
Cook Medicals Reproductive Health Business \| Forecast \| Subsequent Event \| Payables Second Installment
Business Acquisition [Line Items]
Payables incurred in acquisition			50,000,000
Cook Medicals Reproductive Health Business \| Forecast \| Subsequent Event \| Payables Third Installment
Business Acquisition [Line Items]
Payables incurred in acquisition			50,000,000
Cook Medicals Reproductive Health Business \| Forecast \| Subsequent Event \| Payables Fourth Installment
Business Acquisition [Line Items]
Payables incurred in acquisition			$ 50,000,000
Generate Life Sciences
Business Acquisition [Line Items]
Payments to acquire business	$ 1,663,000,000
Ownership percentage	100.00%
Measurement period adjustment to goodwill				$ 115,300,000
Actual revenue generated				249,500,000
Actual net income generated				$ 27,800,000
Goodwill	$ 1,177,300,000
Generate Life Sciences \| Customer relationships
Business Acquisition [Line Items]
Useful life				20 years
Generate Life Sciences \| Trademarks
Business Acquisition [Line Items]
Useful life				15 years
Generate Life Sciences \| Line of Credit \| Term Loan Facility 2021
Business Acquisition [Line Items]
Proceeds from line of credit	$ 1,500,000,000
Privately-Held Medical Device Company, Spectacle Lenses, Portion Attributable To Former Equity Interest Owners
Business Acquisition [Line Items]
Undiscounted range of the contingent consideration, minimum								$ 0
Undiscounted range of the contingent consideration, maximum								$ 139,100,000
Payment to settle former equity interest owners		$ 42,900,000
Equity investment gain realized before acquisition of remaining equity interest				$ 12,200,000
Contingent consideration				$ 31,800,000

Acquisitions and Joint Venture - Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Oct. 31, 2022	Dec. 17, 2021	Oct. 31, 2021
Current assets:
Goodwill	$ 3,609.7		$ 2,574.0
Generate Life Sciences
Current assets:
Cash and cash equivalents		$ 58.6
Trade accounts receivable, net		18.1
Inventories		3.3
Prepaid expense and other current assets		33.5
Total current assets		113.5
Property, plant and equipment		42.6
Goodwill		1,177.3
Other assets		21.5
Total assets acquired		2,128.1
Current liabilities:
Accounts payable		12.6
Employee compensation and benefits		12.3
Deferred revenue		68.0
Other current liabilities		12.4
Total current liabilities		105.3
Deferred tax liabilities		147.3
Lease liabilities		16.6
Deferred revenue		192.2
Other long-term liabilities		3.6
Total liabilities assumed		465.0
Total purchase price		1,663.1
Generate Life Sciences \| Customer relationships
Current assets:
Finite-lived intangibles		718.3
Generate Life Sciences \| Trademarks
Current assets:
Finite-lived intangibles		$ 54.9

Acquisitions and Joint Venture - Proforma Information (Details) - Generate Life Sciences - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Business Acquisition [Line Items]
Revenue	$ 3,344.3	$ 3,183.2
Net income	$ 370.7	$ 2,959.8

Acquisitions and Joint Venture - Contingent Consideration Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 97.4	$ 0.0
Purchase price contingent consideration	1.5	31.3
Payments	(55.2)	0.0
Change in fair value	(10.3)	66.1
Ending balance	$ 33.4	$ 97.4
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expense	Selling, general and administrative expense

Intangible Assets - Goodwill (Details) $ in Millions	12 Months Ended
Intangible Assets - Goodwill (Details) $ in Millions	Oct. 31, 2022 USD ($)
Goodwill [Roll Forward]
Balance, beginning	$ 2,574.0
Net additions	1,184.8
Foreign currency translation adjustment	(149.1)
Balance, ending	3,609.7
CooperVision
Goodwill [Roll Forward]
Balance, beginning	1,841.0
Net additions	0.9
Foreign currency translation adjustment	(131.6)
Balance, ending	1,710.3
CooperSurgical
Goodwill [Roll Forward]
Balance, beginning	733.0
Net additions	1,183.9
Foreign currency translation adjustment	(17.5)
Balance, ending	$ 1,899.4

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Intangible Assets - Narrative (Details)	12 Months Ended
Intangible Assets - Narrative (Details)	Oct. 31, 2022 USD ($) reporting_unit	Oct. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)
Goodwill [Line Items]
Number of reporting units \| reporting_unit	3
Goodwill impairment	$ 0	$ 0	$ 0
Impairment of definite-lived intangible assets	0
Impairment of indefinite-lived intangible assets	0
CooperSurgical
Goodwill [Line Items]
Goodwill deductible for tax purposes	214,100,000	137,200,000
CooperVision
Goodwill [Line Items]
Goodwill deductible for tax purposes	$ 22,400,000	$ 24,600,000

Intangible Assets - Other Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,919.0	$ 2,143.3
Accumulated Amortization	1,044.7	881.9
Intangible assets with definite lives, net	$ 1,874.3	1,261.4
Weighted Average Amortization Period (in years)	16 years
Intangible assets with indefinite lives, net	$ 10.8	10.1
Total other intangibles, net	1,885.1	1,271.5
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	209.6	156.7
Accumulated Amortization	$ 62.4	49.1
Weighted Average Amortization Period (in years)	15 years
Composite intangible asset
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,061.9	1,061.8
Accumulated Amortization	$ 354.0	283.2
Weighted Average Amortization Period (in years)	15 years
Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 504.1	513.0
Accumulated Amortization	$ 317.5	287.9
Weighted Average Amortization Period (in years)	12 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,092.7	378.4
Accumulated Amortization	$ 287.0	240.1
Weighted Average Amortization Period (in years)	19 years
License and distribution rights and other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 50.7	33.4
Accumulated Amortization	$ 23.8	$ 21.6
Weighted Average Amortization Period (in years)	11 years

Intangible Assets - Estimated Amortization Expenses for Intangible Assets with Definite Lives (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 183.2
2024	179.2
2025	169.3
2026	162.0
Thereafter	1,180.6
Intangible assets with definite lives, net	$ 1,874.3	$ 1,261.4

Financing Arrangements - Total Debt (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Short-term Debt
Less: unamortized debt issuance cost	$ 0.0	$ (0.1)
Short-term debt, excluding financing leases	395.7	82.9
Financing lease liabilities	$ 16.9	$ 0.5
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Short-term debt	Short-term debt
Short-term debt	$ 412.6	$ 83.4
Long-term Debt
Less: unamortized debt issuance cost	(3.1)	(0.2)
Long-term debt, excluding financing leases	2,347.1	1,396.1
Financing lease liabilities	$ 3.7	$ 1.5
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term debt	Long-term debt
Long-term debt	$ 2,350.8	$ 1,397.6
Total debt	2,763.4	1,481.0
Overdraft and other credit facilities
Short-term Debt
Short-term debt	57.7	83.0
Term loans
Short-term Debt
Short-term debt	338.0	0.0
Term loans
Long-term Debt
Long-term debt, gross	2,350.0	850.0
Other
Long-term Debt
Long-term debt, gross	0.2	0.2
Revolving Credit Facility \| Line of Credit
Long-term Debt
Long-term debt, gross	$ 0.0	$ 546.1

Financing Arrangements - Narrative (Details) - USD ($)				12 Months Ended
Financing Arrangements - Narrative (Details) - USD ($)	Dec. 17, 2021	Nov. 02, 2021	Apr. 01, 2020	Oct. 31, 2022	Oct. 31, 2021
Term Loan Facility 2021 \| Line of Credit
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount	$ 1,500,000,000
Potential additional borrowing capacity	1,125,000,000
Proceeds from line of credit	$ 1,500,000,000
Interest rate				4.44%
Term Loan Facility 2021 \| Line of Credit \| London Interbank Offered Rate (LIBOR)
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	1.00%
Term Loan Facility 2021 \| Line of Credit \| Fed Funds Effective Rate Overnight Index Swap Rate
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.50%
Term Loan Facility, 2021 Base Rate Loans \| Line of Credit \| London Interbank Offered Rate (LIBOR)
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.00%
Term Loan Facility 2021, Adjusted LIBO Rate Loans \| Line of Credit \| London Interbank Offered Rate (LIBOR)
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.75%
Term Loan Agreement 2021, 364 Day \| Term loans
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt term		364 days
Original debt amount		$ 840,000,000
Repayments of short-term debt				$ 502,000,000
Term Loan Agreement 2021, 364 Day \| Term loans \| London Interbank Offered Rate (LIBOR)
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate		0.60%
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 1,290,000,000
Proceeds from line of credit			$ 445,000,000
Interest rate				4.13%
Debt outstanding				$ 0
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility \| Minimum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.10%
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility \| Maximum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.20%
Credit Agreement 2020 \| Line of Credit \| Term Loan Facility 2020
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 850,000,000
Proceeds from line of credit			850,000,000
Interest rate				4.13%
Debt outstanding				$ 850,000,000
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Potential additional borrowing capacity			$ 1,605,000,000
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020 \| London Interbank Offered Rate (LIBOR) \| Minimum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.75%
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020 \| London Interbank Offered Rate (LIBOR) \| Maximum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			1.50%
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020 \| Base Rate \| Minimum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.00%
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020 \| Base Rate \| Maximum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.50%
European Credit Facilities \| Line of Credit \| Revolving Credit Facility
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount				30,700,000	$ 35,800,000
Debt outstanding				$ 12,300,000
Weighted average interest rate				2.46%
Asian Pacific Credit Facilities - Yen-Denominated \| Line of Credit \| Revolving Credit Facility
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount				$ 73,000,000	$ 95,000,000
Debt outstanding				$ 45,400,000
Weighted average interest rate				0.40%

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Jul. 31, 2021	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021	Oct. 31, 2020
Operating Loss Carryforwards [Line Items]
Effective tax rate		18.80%	(499.10%)
Deferred tax asset, intra-entity sale of certain intellectual property rights				$ 1,987.9
Tax benefit related to remeasurement of deferred tax assets due to UK change in tax rate	$ 536.7
Unrecognized tax benefits		$ 336.9	$ 353.8		$ 58.5
Unrecognized tax benefits that would impact the effective tax rate		324.3	336.5		46.0
Accrued gross interest and penalties related to uncertain tax positions		5.4	$ 6.4		$ 7.3
Significant change in unrecognized tax benefits that is reasonably possible during the next twelve months		9.1
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards		65.4
Federal net operating losses expiring		17.1
Federal net operating losses not subject to expiration		48.3
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards		$ 97.3

Income Taxes - Income Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Income before income taxes:
United States	$ 31.4	$ (31.0)	$ (88.0)
Foreign	443.9	522.5	354.5
Income before income taxes	$ 475.3	$ 491.5	$ 266.5

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Current:
Federal	$ 10.2	$ 21.0	$ 1.4
State	3.8	1.3	1.1
Foreign	21.7	26.7	26.5
Total current income tax expense (benefit)	35.7	49.0	29.0
Deferred:
Federal	10.5	(8.8)	3.2
State	(2.2)	(0.5)	0.8
Foreign	45.6	(2,492.9)	(4.9)
Total deferred income tax expense (benefit)	53.9	(2,502.2)	(0.9)
Provision for income taxes	$ 89.5	$ (2,453.2)	$ 28.1

Income Taxes - Reconciliation between the Expected Provision for Income taxes at the US Federal Statutory Rate and the Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes at United States statutory tax rate	$ 99.8	$ 103.2	$ 56.0
Foreign earnings in jurisdictions with lower tax rates	(22.3)	(43.6)	(54.7)
Foreign earnings subject to United States tax	20.7	25.4	32.0
Excess tax benefits from share-based compensation	(2.6)	(13.0)	(6.2)
Deferred tax asset step-up	(3.4)	3.2	(9.0)
United States provision-to-return	0.5	(1.2)	7.0
Intra-group transfer to UK subsidiary	0.0	(1,987.8)	0.0
Remeasurement of deferred tax assets from UK rate change	0.0	(536.7)	0.0
Change in unrecognized tax benefits	(12.7)	(7.6)	(0.1)
State tax provision	5.0	0.8	1.9
Other, net	4.5	4.1	1.2
Provision for income taxes	$ 89.5	$ (2,453.2)	$ 28.1

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Deferred tax assets:
Accounts receivable	$ 4.9	$ 3.4
Inventories	6.3	6.1
Accrued liabilities, reserves and compensation accruals	79.9	78.1
Foreign deferred tax assets	2,500.5	2,531.5
Share-based compensation	14.5	28.6
Net operating loss and tax credit carryforwards	19.6	19.3
Intangible assets	0.0	6.8
Capitalized research and experimental expenses	15.4	13.5
Total gross deferred tax assets	2,641.1	2,687.3
Less: valuation allowance	(60.1)	(51.8)
Deferred tax assets	2,581.0	2,635.5
Deferred tax liabilities:
Tax deductible goodwill	(39.7)	(34.0)
Intangible assets	(153.8)	0.0
Plant and equipment	(48.8)	(46.5)
Foreign deferred tax liabilities	(45.5)	(32.5)
Total gross deferred tax liabilities	(287.8)	(113.0)
Net deferred tax assets	$ 2,293.2	$ 2,522.5

Income Taxes - Changes in Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning of the period	$ 353.8	$ 58.5
Decrease based on tax positions in prior fiscal years	(12.5)	(8.3)
Increase based on tax positions in current fiscal year		307.2
Settlements	(0.2)	(1.9)
Lapses of statutes of limitations	(4.2)	(1.7)
End of the period	$ 336.9	$ 353.8

Earnings Per Share - Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Earnings Per Share [Abstract]
Net income, basic	$ 385.8	$ 2,944.7	$ 238.4
Net income, diluted	$ 385.8	$ 2,944.7	$ 238.4
Basic:
Weighted average common shares (in shares)	49.3	49.2	49.1
Basic earnings per share (in dollars per share)	$ 7.83	$ 59.80	$ 4.85
Diluted:
Effect of dilutive stock options (in shares)	0.4	0.6	0.5
Diluted weighted average common shares (in shares)	49.7	49.8	49.6
Diluted earnings per share (in dollars per share)	$ 7.76	$ 59.16	$ 4.81

Earnings Per Share - Stock Options to Purchase Common Stock and Restricted Stock Units Not Included in Diluted Earnings Per Share Due to Antidilutive Effect (Details) - $ / shares shares in Thousands	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Range of exercise prices, lower limit (in dollars per share)	$ 300.12	$ 345.74	$ 304.54
Range of exercise prices, higher limit (in dollars per share)	$ 406.17	$ 345.74	$ 304.54
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock option shares and restricted stock units excluded (in shares)	227	107	207
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock option shares and restricted stock units excluded (in shares)	87	2	1

Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Loss) Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 6,942.0	$ 3,824.8	$ 3,628.6
Gross change in value	(90.7)	146.3	(33.0)
Tax effect	(34.8)	(15.6)	8.1
Ending balance	7,174.7	6,942.0	3,824.8
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(341.3)	(472.0)	(447.1)
Ending balance	(466.8)	(341.3)	(472.0)
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(320.3)	(402.3)	(403.2)
Gross change in value	(234.7)	82.2	0.9
Tax effect	0.0	(0.2)	0.0
Ending balance	(555.0)	(320.3)	(402.3)
Derivatives
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	13.1	(13.0)	0.0
Gross change in value	107.4	34.3	(17.1)
Tax effect	(26.1)	(8.2)	4.1
Ending balance	94.4	13.1	(13.0)
Minimum Pension Liability
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(34.1)	(56.7)	(43.9)
Gross change in value	36.6	29.8	(16.8)
Tax effect	(8.7)	(7.2)	4.0
Ending balance	$ (6.2)	$ (34.1)	$ (56.7)

- Definition

Amount before tax, after reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

Amount of tax expense (benefit) allocated to other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

+ Details

Stockholders' Equity - Narrative (Details) - USD ($)	Oct. 31, 2022	Mar. 31, 2017	Dec. 31, 2011
Stockholders' Equity Note [Abstract]
Share repurchase program, maximum amount authorized		$ 1,000,000,000	$ 500,000,000
Share repurchase program, remaining authorized amount	$ 256,400,000

Stockholders' Equity - Share Repurchases (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Stockholders' Equity Note [Abstract]
Number of shares	191,165	69,622
Average repurchase price per share (in dollars per share)	$ 410.4	$ 356.6
Total costs of shares repurchased (in millions)	$ 78.5	$ 24.8	$ 47.8

Stock Plans - Narrative (Details) $ / shares in Units, $ in Millions		1 Months Ended	12 Months Ended
	Mar. 18, 2019 shares	Mar. 31, 2016 director shares	Oct. 31, 2022 USD ($) $ / shares shares	Oct. 31, 2021 USD ($) $ / shares shares	Oct. 31, 2020 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to nonvested options \| $			$ 21.0
Share-based compensation expense \| $			$ 54.2	$ 44.7	$ 38.6
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost expected to be recognized over a remaining weighted-average vesting period			2 years 3 months 18 days
Options granted in period (in shares) \| shares			122,760
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost expected to be recognized over a remaining weighted-average vesting period			2 years 6 months
Total unrecognized compensation cost related to nonvested units \| $			$ 64.4
Performance Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			3 years
Total unrecognized compensation cost expected to be recognized over a remaining weighted-average vesting period			1 year 9 months 18 days
Total unrecognized compensation cost related to nonvested units \| $			$ 11.2
Performance Units \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target percentage of shares earned			0.00%
Performance Units \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target percentage of shares earned			200.00%
Third Amended and Restated 2007 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of non-employee directors in committee \| director		2
Number of shares authorized to be granted \| shares		6,930,000
Shares remaining for future grant (in shares) \| shares			690,596
Third Amended and Restated 2007 Long-Term Incentive Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value of each option granted (in dollars per share) \| $ / shares			$ 90.41	$ 84.10	$ 70.45
Total intrinsic value of options exercised \| $			$ 6.6	$ 64.7	$ 22.6
Award expiration date (no more than)			10 years
Third Amended and Restated 2007 Long-Term Incentive Plan \| Stock Options \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			3 years
Third Amended and Restated 2007 Long-Term Incentive Plan \| Stock Options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			5 years
Third Amended and Restated 2007 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			3 years
Third Amended and Restated 2007 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			5 years
2020 Directors Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			1 year
Award expiration date (no more than)			10 years
Employee Stock Purchase Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to be granted \| shares	1,000,000
Exercise price percentage of fair market value on date of grant of awards	85.00%
Number of shares issued to employees \| shares			22,695	17,575
Number of shares remaining available for future issuance \| shares			948,090
Share-based compensation expense \| $			$ 1.1	$ 1.0

Stock Plans - Compensation Expense and Related Income Tax Benefit for Share-Based Awards (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	$ 54.2	$ 44.7	$ 38.6
Related income tax benefit	5.0	5.6	4.8
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	46.7	38.4	32.2
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	4.5	3.9	4.0
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	$ 3.0	$ 2.4	$ 2.4

Stock Plans - Assumptions Used in Estimating Fair Value of Stock Options Award Granted (Details)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life			4 years 4 months 24 days
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	4 years 1 month 6 days	4 years
Expected volatility	25.80%	30.30%	24.50%
Risk-free interest rate	1.10%	0.30%	1.60%
Dividend yield	0.02%	0.02%	0.02%

Stock Plans - Stock Option Plans (Details)	12 Months Ended
Stock Plans - Stock Option Plans (Details)	Oct. 31, 2022 USD ($) $ / shares shares
Number of Shares
Vested and expected to vest at end of period (in shares) \| shares	1,038,594
Vested and exercisable at end of period (in shares) \| shares	624,512
Weighted- Average Exercise Price Per Share
Vested and expected to vest at end of period (in dollars per share) \| $ / shares	$ 262.91
Vested and exercisable at end of period (in dollars per share) \| $ / shares	$ 223.45
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Vested and expected to vest at end of period, Weighted-Average Remaining Contractual Term (in years)	5 years 8 months 12 days
Vested and exercisable at end of period, Weighted-Average Remaining Contractual Term (in years)	4 years 6 months 25 days
Vested and expected to vest at end of period, Aggregate Intrinsic Value \| $	$ 38,806,329
Vested and exercisable at end of period, Aggregate Intrinsic Value \| $	$ 35,586,767
Stock Options
Number of Shares
Outstanding, beginning balance (in shares) \| shares	972,692
Granted (in shares) \| shares	122,760
Exercised (in shares) \| shares	(26,866)
Forfeited or expired (in shares) \| shares	(4,743)
Outstanding, ending balance (in shares) \| shares	1,063,843
Weighted- Average Exercise Price Per Share
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 245.09
Granted (in dollars per share) \| $ / shares	403.44
Exercised (in dollars per share) \| $ / shares	171.87
Forfeited or expired (in dollars per share) \| $ / shares	325.21
Outstanding, ending balance (in dollars per share) \| $ / shares	$ 264.85
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, ending balance, Weighted Average Remaining Contractual Term (in years)	5 years 9 months

Stock Plans - Non-Vested RSUs (Details) - Restricted Stock Units (RSUs)	12 Months Ended
	Oct. 31, 2022 $ / shares shares
Number of Shares
Nonvested RSUs, beginning balance (in shares) \| shares	317,335
Granted (in shares) \| shares	113,079
Vested and issued (in shares) \| shares	(113,301)
Forfeited or expired (in shares) \| shares	(27,875)
Nonvested RSUs, ending balance (in shares) \| shares	289,238
Weighted- Average Grant Date Fair Value Per Share
Non-vested RSUs, beginning balance (in dollars per share) \| $ / shares	$ 293.80
Granted (in dollars per share) \| $ / shares	399.21
Vested and issued (in dollars per share) \| $ / shares	271.74
Forfeited or exercised (in dollars per share) \| $ / shares	324.67
Non-vested RSUs, ending balance (in dollars per share) \| $ / shares	$ 340.68

Employee Benefits - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 134.9	$ 207.6	$ 195.8
Discount rate	2.76%	2.78%	3.13%
Discount rate, decrease	0.02%
Projected defined benefit plan benefit obligation	$ 217.2
Projected defined accumulated benefit obligation	194.2
Defined benefit obligation, actuarial gain (loss)	$ 93.2	$ (2.0)	$ (20.0)
Expected long-term return on diversified portfolio	8.00%
Company's contribution to the pension plan	$ 0.0	12.7	23.4
Maximum annual contributions per employee in 401k savings plan	75.00%
Contributions by employer in 401k savings plan	$ 9.0	$ 7.2	$ 6.8
Minimum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Diversified portfolio, allocation of assets in equities	50.00%
Maximum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Diversified portfolio, allocation of assets in equities	70.00%
Change In Assumptions For Defined Benefit Plans, Change In Key Assumptions
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	$ 97.1
Change In Assumptions For Defined Benefit Plans, Change In Demographic Experience
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	(3.9)
Change In Assumptions For Defined Benefit Plans, Change In Discount Rate
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	72.7
Change In Assumptions For Defined Benefit Plans, Change In Assumed Payment Form Election Probabilities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	0.3
Change In Assumptions For Defined Benefit Plans, Change In Lump Sum Determination
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	$ 24.1

Employee Benefits - Changes in Benefit Obligation, Changes in Plan Assets and Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Change in benefit obligation
Benefit obligation, beginning of year	$ 230.9	$ 218.8	$ 189.7
Service cost	18.3	17.2	13.9
Interest cost	5.1	4.4	5.2
Benefits paid	(13.1)	(11.5)	(10.0)
Actuarial (gain)/loss	(93.2)	2.0	20.0
Benefit obligation, end of year	$ 148.0	$ 230.9	$ 218.8
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Accrued pension liability and other	Accrued pension liability and other	Accrued pension liability and other
Change in plan assets
Fair value of plan assets, beginning of year	$ 199.5	$ 159.5	$ 136.0
Actual return on plan assets	(43.5)	38.8	10.1
Employer contributions	0.0	12.7	23.4
Benefits paid	(13.1)	(11.5)	(10.0)
Fair value of plan assets, end of year	142.9	199.5	159.5
Funded status at end of year	$ (5.1)	$ (31.4)	$ (59.3)

Employee Benefits - Amounts Recognized in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Amounts recognized in accumulated other comprehensive income consist of:
Net loss	$ 8.0	$ 44.4	$ 74.2
Accumulated other comprehensive income	$ 8.0	$ 44.4	$ 74.2

Employee Benefits - Reconciliation of Prepaid (Accrued) Pension Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Reconciliation of (prepaid) accrued pension cost:
(Prepaid)/Accrued pension cost at prior fiscal year end	$ (13.0)	$ (14.8)	$ (3.7)
Net periodic benefit cost	10.1	14.5	12.3
Contributions made during the year	0.0	(12.7)	(23.4)
(Prepaid)/Accrued pension cost at fiscal year end	$ (2.9)	$ (13.0)	$ (14.8)

- Definition

Amount of contribution received by defined benefit plan from employer which increases plan assets.

+ References + Details

Employee Benefits - Components of Net Periodic Pension Costs and Other Amounts Recognized in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Components of net periodic benefit cost and other amounts recognized in the Consolidated Statements of Income:
Service cost	$ 18.3	$ 17.2	$ 13.9
Interest cost	$ 5.1	$ 4.4	$ 5.2
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)
Expected return on plan assets	$ (15.5)	$ (12.5)	$ (10.8)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Immediate Recognition of Actuarial Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)
Recognized actuarial loss	$ 2.2	$ 5.4	$ 4.0
Net periodic pension cost	$ 10.1	$ 14.5	$ 12.3

Employee Benefits - Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Other changes in plan assets and benefit obligations recognized in other comprehensive income:
Net (gain) loss	$ (34.1)	$ (24.4)	$ 20.8
Amortizations of net gain	(2.5)	(5.4)	(4.0)
Total recognized in other comprehensive (income) loss	(36.6)	(29.8)	16.8
Total recognized in net periodic benefit cost and other comprehensive (income) loss	$ (26.2)	$ (15.2)	$ 29.0

Employee Benefits - Weighted-Average Assumptions Used in Computing Net Periodic Pension Cost and Projected Benefit Obligation (Details)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Discount rate for determining net periodic pension cost:
Projected Benefit Obligation	2.76%	2.78%	3.13%
Service Cost	2.79%	2.86%	3.18%
Interest Cost	2.28%	2.07%	2.78%
Discount rate for determining benefit obligations at year end	5.74%	2.76%	2.78%
Rate of compensation increase for determining expense	3.60%	3.60%	3.60%
Rate of compensation increase for determining benefit obligations at year end	3.60%	3.60%	3.60%
Expected rate of return on plan assets for determining net periodic pension cost	8.00%	8.00%	8.00%
Expected rate of return on plan assets at year end	8.00%	8.00%	8.00%

Employee Benefits - Weighted-Average Asset Allocations by Asset Category (Details)	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	100.00%	100.00%	100.00%
Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	2.00%	5.00%	11.80%
Equity mutual funds
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	65.80%	62.80%	57.70%
Hedging Strategy Funds
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	5.20%	4.70%	4.30%
Bond mutual funds
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	27.00%	27.50%	26.20%

Employee Benefits - Fair Value Measurement of Plan Assets (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	$ 142.9	$ 199.5	$ 159.5	$ 136.0
Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	118.8
Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	24.1
Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	2.9
Cash and cash equivalents \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	2.9
Cash and cash equivalents \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Cash and cash equivalents \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Equity mutual funds
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	93.9
Equity mutual funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	93.9
Equity mutual funds \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Equity mutual funds \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Hedging Strategy Funds
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	7.5
Hedging Strategy Funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	7.5
Hedging Strategy Funds \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Hedging Strategy Funds \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Bond mutual funds
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	38.6
Bond mutual funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	14.5
Bond mutual funds \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	24.1
Bond mutual funds \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	$ 0.0

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

Employee Benefits - Estimated Future Benefit Payments (Details) $ in Millions	Oct. 31, 2022 USD ($)
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
2023	$ 9.4
2024	11.0
2025	11.9
2026	11.4
2027	11.9
2028-2032	$ 66.1

Business Segment Information - Narrative (Details)	12 Months Ended
Business Segment Information - Narrative (Details)	Oct. 31, 2022 segment
Segment Reporting [Abstract]
Number of operating segments	2

Business Segment Information - Business Segment Net Sales (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Segment Reporting Information [Line Items]
Net sales	$ 3,308.4	$ 2,922.5	$ 2,430.9
CooperVision
Segment Reporting Information [Line Items]
Net sales	2,243.3	2,152.0	1,843.0
CooperSurgical
Segment Reporting Information [Line Items]
Net sales	1,065.1	770.5	587.9
Toric lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	737.4	697.5	598.2
Multifocal lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	264.4	238.6	197.0
Single-use sphere lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	661.6	616.3	529.0
Non single-use sphere, other \| CooperVision
Segment Reporting Information [Line Items]
Net sales	579.9	599.6	518.8
Office and surgical products \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales	633.6	451.3	358.8
Fertility \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales	$ 431.5	$ 319.2	$ 229.1

Business Segment Information - Business Segment Information (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Segment Reporting Information [Line Items]
Net sales	$ 3,308.4	$ 2,922.5	$ 2,430.9
Operating income (loss)	507.6	505.8	311.8
Interest expense	57.3	23.1	36.8
Other expense (income), net	(25.0)	(8.8)	8.5
Income before income taxes	475.3	491.5	266.5
Identifiable assets	11,492.3	9,606.2	6,737.5
Depreciation expense	166.6	163.2	149.9
Amortization expense	179.5	146.1	137.2
Capital expenditures	242.0	214.4	310.4
CooperVision
Segment Reporting Information [Line Items]
Net sales	2,243.3	2,152.0	1,843.0
CooperSurgical
Segment Reporting Information [Line Items]
Net sales	1,065.1	770.5	587.9
Corporate
Segment Reporting Information [Line Items]
Net sales	0.0	0.0	0.0
Operating income (loss)	(53.8)	(47.3)	(49.2)
Identifiable assets	305.6	244.7	207.4
Depreciation expense	0.0	0.0	0.0
Amortization expense	0.0	0.0	0.0
Capital expenditures	0.0	0.0	0.0
Operating Segments \| CooperVision
Segment Reporting Information [Line Items]
Net sales	2,243.3	2,152.0	1,843.0
Operating income (loss)	494.3	481.3	375.7
Identifiable assets	6,778.9	6,965.9	4,236.3
Depreciation expense	144.5	148.3	138.2
Amortization expense	32.3	35.7	32.4
Capital expenditures	223.0	190.0	260.3
Operating Segments \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales	1,065.1	770.5	587.9
Operating income (loss)	67.1	71.8	(14.7)
Identifiable assets	4,407.8	2,395.6	2,293.8
Depreciation expense	22.1	14.9	11.7
Amortization expense	147.2	110.4	104.8
Capital expenditures	$ 19.0	$ 24.4	$ 50.1

Business Segment Information - Information by Geographical Area by Country of Domicile (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Segment Reporting Information [Line Items]
Net sales	$ (3,308.4)	$ (2,922.5)	$ (2,430.9)
Operating income	507.6	505.8	311.8
Long-lived assets	1,432.9	1,347.6	1,281.9
United States
Segment Reporting Information [Line Items]
Net sales	(1,638.5)	(1,339.2)	(1,103.6)
Europe
Segment Reporting Information [Line Items]
Net sales	(987.2)	(957.9)	(789.8)
Rest of World
Segment Reporting Information [Line Items]
Net sales	(682.7)	(625.4)	(537.5)
Geography Eliminations \| United States
Segment Reporting Information [Line Items]
Net sales	514.4	494.9	391.7
Geography Eliminations \| Europe
Segment Reporting Information [Line Items]
Net sales	897.3	815.1	327.1
Geography Eliminations \| Rest of World
Segment Reporting Information [Line Items]
Net sales	1,411.7	1,310.0	718.8
Reportable Geographical Components \| United States
Segment Reporting Information [Line Items]
Net sales	(2,152.9)	(1,834.1)	(1,495.3)
Operating income	71.8	(26.8)	(14.5)
Long-lived assets	856.1	737.5	721.3
Reportable Geographical Components \| Europe
Segment Reporting Information [Line Items]
Net sales	(1,884.5)	(1,773.0)	(1,116.9)
Operating income	403.8	416.2	21.9
Long-lived assets	310.8	377.2	363.0
Eliminations, Corporate and Reconciling Items \| Rest of World
Segment Reporting Information [Line Items]
Net sales	729.0	684.6	181.3
Operating income	32.0	116.4	304.4
Long-lived assets	$ 266.0	$ 232.9	$ 197.6

Financial Derivatives and Hedging - Narrative (Details) $ in Millions	12 Months Ended
	Oct. 31, 2022 USD ($) interest_rate_swap_contract	Oct. 31, 2021 USD ($)	Apr. 06, 2020 USD ($) interest_rate_swap_contract
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Pre-tax impact of gain (loss) on derivatives recognized in other comprehensive income (loss)	$ 124.5	$ 17.2
Gain (loss) on derivatives recognized in other comprehensive income (loss), net of tax	30.1	$ 13.1
Derivative loss expected to be realized in earnings over the next twelve months	38.3
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of interest rate swap contracts held \| interest_rate_swap_contract			6
Derivative notional amount	$ 1,000.0		$ 1,500.0
Number of interest rate swap contracts matured \| interest_rate_swap_contract	3
Interest rate swap contracts, contract term (or less)	5 years

Financial Derivatives and Hedging - Derivative Instruments Recognized in Condensed Consolidated Statements of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Interest expense \| Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Loss recognized on derivatives within interest expense	$ (2.3)	$ 8.0	$ 3.7

Financial Derivatives and Hedging - Changes in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]
Beginning balance	$ 6,942.0	$ 3,824.8	$ 3,628.6
Amount recognized in other comprehensive income on interest rate swaps contracts, net of tax	79.7	20.0
Amount reclassified from other comprehensive income into earnings, net of tax	1.7	6.1
Ending balance	7,174.7	6,942.0	3,824.8
Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]
Beginning balance	17.2	(17.1)
Ending balance	124.5	17.2	(17.1)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]
Beginning balance	13.1	(13.0)	0.0
Amount recognized in other comprehensive income on interest rate swap contracts, gross	105.1	26.3
Amount reclassified from other comprehensive income into earnings, gross	2.2	8.0
Ending balance	$ 94.4	$ 13.1	$ (13.0)

- Definition

+ References

+ Details

Schedule II (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance Beginning of Year	$ 51.8	$ 45.3	$ 41.5
Additions	13.3	8.8	5.9
Reductions/ Charges	(5.0)	(2.3)	(2.1)
Balance at End of Year	$ 60.1	$ 51.8	$ 45.3